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Abstract 
Human Immunodeficiency Virus (HIV), a chronic medical condition characterized by 
cycles of wellness and illness, has the potential to decrease the physical activity levels 
and functional independence of infected individuals.  Although antiretroviral therapy has 
been credited with improving and maintaining the immune status of infected patients by 
increasing cluster of differention 4 (CD4) count and suppressing viral load, the short- and 
long-term side effects of antiretroviral medication and the possible negative impact of 
these side effects on physical well-being have not yet been fully investigated.  Therefore, 
I assessed the relationship between CD4 count, habitual physical activity levels and 
functional independence in a group of HIV positive South African adults either taking or 
not taking antiretroviral medication.  I also compared the aerobic capacity, muscle 
strength and physical activity levels (activity counts) of age-matched black HIV negative 
females and HIV positive females who were taking antiretroviral medication. 
 
For the first part of the study, a Lifestyle and Physical Activity Questionnaire was 
completed by 186 black* male and female HIV positive outpatients who were recruited 
from a Johannesburg based antiretroviral roll out site.  Of these patients, 121 were on first 
line antiretroviral treatment (median time of seven months), and 65 patients were not 
taking any medication.  The questionnaire, as well as recording HIV history and current 
CD4 count, assessed each patient’s ability to independently perform one or more tasks of 
daily living as well as his/her monthly occupational, household and recreational physical 
activity levels.  From the subjects’ responses, a total metabolic equivalent (MET) score 
for one month was calculated.  The second part of the study assessed the full blood 
counts, aerobic capacity (submaximal bicycle ergometer test), lower limb strength 
(isokinetic dynamometry), hand grip strength (hand dynamometer) and seven day 
physical activity counts (actigraphy) of ten HIV positive black females recruited from the 
same Johannesburg antiretroviral roll out site.  All of these patients had been taking first 
line antiretroviral treatment for a median time period of seven months.  Ten HIV negative 
age-matched black females acted as their controls. 
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From the questionnaire, significant correlations were observed between CD4 count and 
length of time on antiretroviral medication (P < 0.0001; r = 0.45), and between CD4 
count and total monthly physical activity level (P = 0.0067; r = 0.20).  Patients who 
considered themselves functionally independent had a significantly higher CD4 count 
that those patients who required help from others (P = 0.0031).  The second part of the 
study revealed no significant difference in aerobic capacity, lower limb muscle strength 
(peak torque), handgrip strength and seven day physical activity counts between the 
female HIV positive patients and HIV negative controls. 
 
My results show that the use of antiretroviral medication (median time of seven months) 
increases CD4 count which translates into an increased habitual physical activity level 
and greater sense of functional independence.  I have also shown that HIV positive 
females who are taking antiretroviral medication have an aerobic capacity, leg strength, 
handgrip strength and physical activity count which is not statistically different to their 
HIV negative counterparts.  In this sample, the side effects associated with the 
administration of antiretroviral medication did not negatively impact on physical well-
being.  However, more research needs to be conducted on the possible physical activity 
limiting side effects of longer term antiretroviral medication administration, which may 
limit habitual physical activity levels. 
 
* Footnote: Race does not refer to any biological attributes but rather to the compulsory classification of 
people into the Population Registration Act.  Although the act has been amended, these categories are still 
powerful and commonly used by the South African Government and statistical services. 
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Chapter 1 – Introduction 
 
1.1 Literature Review 
Human immunodeficiency virus (HIV) is a human retrovirus and is believed to be 
the causative organism of Acquired Immune Deficiency Syndrome (AIDS) 
(Griffen, 2003; Fauci et al., 1994).  First being identified in 1981, HIV continues 
to be a rapidly growing epidemic, with approximately 37.8 million people 
worldwide living with the disease (UNAIDS, 2004).  The World Health 
Organisation (WHO) estimated that 40.3 million people were living with HIV 
disease at the end of 2005 (WHO, 2006).  This number continues to grow, 
regardless of improvements in treatment and prevention campaigns. 
 
HIV and AIDS is a pandemic with cases reported from every continent (Fauci et 
al., 1994).  However, sub-Saharan Africa has the highest incidence of HIV/AIDS 
in the world.  In 2003, an estimated 2.3 million people in this region died of 
HIV/AIDS.  At the same time an estimated 3.2 million people acquired the 
infection in the same area (Stewart et al., 2004).  The Joint United Nations 
Programme on HIV/AIDS (UNAIDS) and WHO estimated that 25.8 million 
people in the sub-Saharan region were living with HIV at the end of 2005 (WHO, 
2006).  However, it is thought that the percentage of adults infected with HIV in 
this region has remained stable in recent years (UNAIDS, 2004).   
 
1.1.1 HIV in South Africa 
At the end of 2002, it was estimated that there were 5.3 million South Africans 
living with HIV, with a population prevalence rate of 21.5% (UNAIDS, 2004).  
South Africa (SA) is said to have a higher population of people infected with HIV 
than any other country (WHO, 2006).  By February 2003, approximately 30 000 
people were receiving antiretroviral (ARV) treatment.  Provision was mainly to 
individuals who had medical aid coverage through the private health sector and to 
some individuals receiving treatment through non-profit organizations (Stewart et 
al., 2005).  It was further estimated that approximately 500 000 South Africans 
had AIDS defining illnesses and were in need of ARV treatment.  In November 
2003, the South African government released their “Operational Plan for 
Comprehensive HIV and AIDS Care and Treatment”.  The Operational Plan 
focuses on providing comprehensive care, including ARV medication in order to 
provide care to all South Africans and permanent residents who require it.  This 
plan outlines a multi-sector response to the epidemic, and recognizes the crucial 
role of ARVs in the treatment of people with HIV/AIDS (Stewart et al., 2005).  
By August 2004, the Department of Health (DoH) estimated that ARV treatment 
was being provided to 11 253 patients, with the number increasing substantially to 
19 500 patients by the end of October 2004.  The Department of Health indicated 
that almost 30 000 patients were on treatment by February 2005 (Stewart et al., 
2005).  However, it is unclear whether these figures include both private and 
public health sectors.  Also, these figures provided by the Department of Health 
differ considerably from the estimates reported by WHO.  At the end of 2004, 
WHO estimated that between 40 000 and 67 000 South Africans were receiving 
treatment (Dorrington et al., 2004).  It was also stated that the number of 
individuals receiving ARV treatment rose to between 178 000 and 235 000 by the 
end of 2005 (WHO, 2006).  The exact number of people receiving ARV treatment 
in SA is still unknown.  From the information released by the Department of 
Health it is estimated that only approximately 21,5% HIV positive individuals in 
SA were receiving treatment at the end of 2004.  Due to the lack of access to 
ARV medication, it might be worth considering alternative therapies for 
increasing wellness and quality of life in HIV positive individuals not receiving 
ARV medication. 
 
1.1.2 Clinical symptoms of HIV infection 
HIV disease is characterized by a large immunodeficiency caused by a 
progressive quantitative and qualitative loss of the CD4 subset of T lymphocytes 
(Eichner et al., 1994; Fauci et al., 1994).  Although the CD4 T cell is the 
predominant cell type that is infected with HIV, almost any human cell which 
expresses the CD4 molecule is capable of binding to and becoming infected with 
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HIV.  The decline in the CD4 cell count results in an increased loss of integrity of 
the immune system and the development of a wide variety of clinical signs and 
symptoms. 
 
It was recognized early that CD4 T cells are the main targets of HIV infection and 
that a substantial reduction in the number of CD4 cells is required for the 
development of AIDS (Fahey et al., 1990).  HIV disease can therefore be divided 
into specific stages on the basis of the amount of immunosuppression.  These 
stages are an early stage (CD4 cell count > 500 cells per mm3), an intermediate 
stage (CD4 cell count between 200 and 500 cells per mm3), and an advanced 
stage (CD4 cell count < 200 cells per mm3) (Fauci et al., 1994).  In early HIV 
infection, immunological status (i.e., CD4 cell count) is one of several factors that 
have been established as prognostic of risk for progression to AIDS (Chlebowski 
et al., 1989).  The majority of AIDS defining opportunistic infections occur 
within the advanced stage. 
   
WHO classifies HIV/AIDS into four clinical stages (WHO, 2005), based on signs 
and symptoms with which HIV positive patients present.  These four clinical 
stages are shown in Table 1.1. 
 
The staging system below relies more on clinical conditions for classification of 
HIV.  For the purposes of this text, separate sections will deal with primary 
infection, asymptomatic latent disease, symptomatic latent disease and AIDS. 
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__________________________________________________________________ 
Table 1.1 Summary of World Health Organisation (WHO) Clinical Staging of 
HIV/AIDS for adults and adolescents (adapted from Department of Health, 2003: 
Standard Treatment Guidelines and Essential Drugs List for South Africa). 
Primary HIV Infection - Seroconversion                 .   
Asymptomatic 
Acute retroviral syndrome (flu-like illness) 
 
Clinical stage 1                   . 
Asymptomatic for approximately 8 – 10 years 
HIV replication rate is high but immune system still capable of containing the infection 
Persistent generalized lymphadenopathy (PGL) 
Performance Scale 1: asymptomatic, normal activity 
 
Clinical stage 2                   . 
Moderate unexplained body mass loss (< 10% of presumed or measured body body mass) 
Minor mucocutaneous manifestations (recurrent oral ulcerations, fungal nail infections) 
Recurrent respiratory tract infections 
Herpes zoster within last five years 
Performance scale 2: symptomatic, normal activity 
 
Clinical stage 3                   . 
Conditions where a presumptive diagnosis can be made of clinical signs or simple investigations 
Severe body mass loss (> 10% of presumed or measured body body mass) 
Unexplained chronic diarrhea for longer than one month 
Unexplained persistent fever (intermittent or constant for longer than one month) 
Oral candidiasis 
Pulmonary tuberculosis (TB) diagnosed in last two years 
Severe presumed bacterial infections (e.g. pneumonia, meningitis) 
Conditions where confirmatory diagnostic testing is necessary 
Unexplained anemia (< 8g/dl) and or neutropenia (< 500/mm3) and thrombocytopenia (< 
50 000/mm3) for more than one month 
 Performance Scale 3: bedridden less than 50% of the day during the last month 
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Clinical stage 4                   . 
Conditions where a presumptive diagnosis can be made of clinical signs or simple investigations 
HIV wasting syndrome: body mass loss of more than 10% of body body mass, plus either 
the following persisting for more than one month: Unexplained chronic diarrhea, chronic 
weakness, unexplained prolonged fever 
Recurrent severe or radiological bacterial pneumonia 
Chronic herpes simplex infection (oralabial, genital or anorectal of more than one 
month’s duration). 
Extrapulmonary TB 
Kaposi’s sarcoma 
Conditions where confirmatory diagnostic testing is necessary 
Extrapulmonary cryptococcosis including meningitis  
Disseminated non-tuberculous mycobacteria infection 
Progressive multifocal leukoencephalopathy (PML) 
Performance scale 4: bedridden for more than 50% of the day during the last month 
 
1.1.3 Opportunistic infections associated with HIV 
HIV disease may present with opportunistic or secondary infections due to 
lowered immune competence (Kotler et al., 1985).  These infections are a late 
complication of HIV infection, for the most part occurring in patients with a CD4 
cell count of less than 200 cells per mm3 (Fauci et al., 1994).  Opportunistic 
infections are the leading cause of morbidity and mortality in patients infected 
with HIV. 
 
Virtually every organ system in the body is vulnerable to disease either as a direct 
consequence of HIV infection, or secondary to other infections or neoplastic 
conditions (Fauci et al., 1994).  While the majority of these diseases are due to 
opportunistic infections, there are also a variety of clinical problems for which no 
specific pathogens are clearly identified.  Pulmonary disease is seen in virtually 
every patient.  Pneumonia is the most common manifestation of pulmonary 
disease.  Sinusitis is a common respiratory tract complication of HIV disease, and 
is seen at all stages of infection.  Gastrointestinal disease is a common feature of 
HIV infection and is most frequently due to a secondary infection.  Infections of 
the small and large intestine are among the most significant gastrointestinal 
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problems in HIV infected individuals and usually present with diarrhoea, 
abdominal pain, occasional fever, and in severe cases, body mass loss.   
 
Pneumocystis carinii is one of the most common infections associated with 
advanced HIV infection (Wilkin et al., 1999; Fauci et al., 1994).  Another 
protozoal infection associated with HIV is toxoplasmosis, the most common 
secondary central nervous system (CNS) infection in patients with advanced HIV 
disease or AIDS (Fauci et al., 1994).  Tuberculosis (TB) is a common bacterial 
opportunistic infection with HIV (Grimwood, 2004).  TB is likely the leading 
cause of death among HIV-infected persons (Stewart et al., 2004; Department of 
Health, 2003).  TB accounted for an estimated 30% of all AIDS related deaths in 
1999 (Statistics SA, 2005).  Fungal infections include oral and vaginal Candida 
(thrush).  These types of infections are seen early in the course of HIV infection, 
indicating the onset of clinically apparent immunodeficiency (Fauci et al., 1994).   
A variety of neoplastic and premalignant diseases occur with increased frequency 
in HIV infected patients, including Karposi’s sarcoma and lymphoma (Fauci et 
al., 1994).   
 
Hematological problems, such as anemia, neutropenia and thrombocytopenia, are 
common throughout the course of HIV infection and occur as a direct result of 
HIV, as a manifestation of opportunistic infections and as a side effect of therapy 
(Fauci et al., 1994).  Renal disease may be associated with HIV infection, and 
although it is often the result of a drug-induced injury, a significant portion of 
patients infected with HIV develop renal disease.  This type of renal disease is 
designated as HIV-associated nephropathy.  Dermatological problems include 
seborrheic dermatitis, eosinophilic pustular folliculitis, and several minor 
cutaneous infections. 
 
Prophylactic medication is used to treat opportunistic infections (Griffen, 2003).  
The following conditions are indicated before opportunistic infections can be 
treated with prophylactics (DoH, 2003): 
 6
• WHO Clinical stage 3 or 4 for HIV infection and disease in adults and 
adolescents 
• CD4 cell count less than 200 cells per mm3 
Prophylaxis is discontinued if the CD4 cell count increases to more than 200 cells 
per mm3 on ARV therapy (DoH, 2003). 
 
1.1.4 Physiology of HIV infection 
HIV infection is associated with various physiological symptoms or 
manifestations.  As the disease progresses, various metabolic syndromes are 
observed (Stringer et al., 2001).  These syndromes include body mass loss and 
muscle wasting and are discussed below.  Some metabolic syndromes can be 
attributed to use of ARV medication. 
  
Severe body mass loss and body wasting is a major component of HIV infection 
(Hellerstein et al., 1990; Chlebowski et al., 1989; Kotler et al., 1985). In HIV 
infection, each component of the energy-balance equation (caloric intake, total 
energy expenditure (EE), resting EE, dietary expenditure and energy expended in 
activity) may be disturbed (Grunfeld et al., 1992).  Opportunistic infections and 
their associated symptoms (including anorexia, nausea, vomiting, malabsorption, 
and diarrhea) limit food intake and intensify resting energy demands, increasing 
nutritional needs (DoH, 2003), so that body mass cannot be maintained.  The 
effect of the wasting process on morbidity plays a major role in the decreased 
quality of life of these patients (Hellerstein et al., 1990).  For undernourished 
HIV-infected people, the resulting trend of inadequate nutritional intake, inability 
to maintain body mass and lean tissue mass, micronutrient deficiency and 
increased susceptibility to opportunistic infections accelerates the development of 
AIDS (DoH, 2003). 
 
AIDS wasting syndrome (AWS) is defined as the loss of body mass from 
decreased calorie intake, decreased appetite, and starvation.  AWS is diagnosed 
when there is an involuntary loss of greater than ten percent body mass (Stringer 
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et al., 2001).  Loss of body mass from inadequate calorie intake usually occurs 
during serious opportunistic infections when appetite is impaired.  Increased 
production of cytokines (such as tumor necrosis factor, which has been associated 
with the presence of severe infections and may result in abnormal metabolism) 
has also been suggested to contribute to malnutrition and subsequent body mass 
loss (Grunfeld et al., 1992; Chlebowski et al., 1989).  Diarrhoea and 
malabsorption are additional contributory factors common to AWS.   
 
Severe body mass loss is a major component of the clinical syndrome in patients 
with HIV (Chlebowski et al., 1989).  Body mass loss of more than ten percent of 
pre-infection body mass during the course of HIV infection is associated with 
increased mortality and adverse outcomes (Stringer et al., 2001; Bhasin et al., 
2000; Kotler et al., 1985).  However, lean body mass loss is a more reliable 
estimate of the degree of wasting than is body mass (Grunfeld et al., 1993).  Body 
fat content is not a reliable marker of wasting as some patients may lose lean body 
mass with little loss of fat (Grunfeld et al., 1992). 
 
Cachexia is defined as the loss of lean body mass despite adequate or even 
increased caloric intake and is likely to be associated with hypermetabolism 
inflammation caused by increased levels of cytokines (Grunfeld et al., 1992).  
Resting energy expenditure (EE) or metabolic rate is increased during acute 
infection and is thought to significantly contribute to body mass loss (Grunfeld, et 
al., 1992).  It has been concluded that the loss of lean body mass in men infected 
with HIV is dependent on the percentage body fat before the body mass loss 
(Forrester et al., 2002).  This type of loss of lean body mass, especially muscle, is 
associated with active viral replication and opportunistic infections, and can be 
treated with appropriate ARV therapy (Stringer et al., 2001). 
 
Sarcopenia, also called muscle wasting, occurs with AWS and cachexia and 
results in decreased lean body mass.  Sarcopenia can also result from muscle 
myopathy caused by the effect of a specific ARV treatment called nucleoside 
reverse transcriptase inhibitors (NRTIs) on mitochondrial function.  Sarcopenia 
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can also result from myositis or it may be related to an HIV-induced myopathy 
(Stringer et al., 2001). 
 
Decreased muscle mass causes a decrease in the overall functional status of HIV 
infected individuals, including decreased exercise performance, aerobic capacity 
and lower-body muscle strength (Grinspoon et al., 1996).  Weakness and fatigue 
are among the most troubling and debilitating symptoms reported by these 
patients (Hellerstein et al., 1990). Inactivity and the accompanying symptoms also 
lead to a decrease in muscle mass and the inability to restore muscle mass after 
bouts of wasting, resulting in a loss of functional capacity.  Therefore, the role of 
regular exercise in preventing this loss of lean body mass, and subsequent 
functional capacity, becomes more important.  Physical activity (PA) is required 
for the maintenance of muscle mass (Grunfeld et al., 1992), as it prevents the loss 
of muscle function that accompanies a sedentary lifestyle (Jones et al., 2001).  
Maintaining a pattern of regular exercise is helpful for maintaining muscle mass 
and strength (Willardson, 2004).  Resistance exercise in particular has 
demonstrated increased muscle protein synthesis, as well as decreased myostatin 
(protein product of the gene that regulates muscle growth).  High levels of 
myostatin have been associated with muscle wasting in AIDS patients.  Therefore 
exercise is important for restoring muscle size and strength through increases in 
muscle protein synthesis and motor unit synchronization. 
 
1.1.5 Treatment of HIV  
Treatment of patients with HIV infection not only requires a comprehensive 
knowledge of the disease process itself, but also the patient’s psychological ability 
to deal with the problems of a chronic, life-threatening illness.  Although the 
infection cannot be cured, chances of survival and quality of life have been 
improved with the use of specific antiretroviral (ARV) therapy and antimicrobial 
treatment and prophylactic medication (Griffen, 2003; Fauci et al., 1994). 
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The provision of ARV therapy has been credited with having a significantly 
positive effect on the lives of people living with HIV/AIDS (Stewart et al., 2004). 
ARV therapy targets HIV at various points of its cycle.  The primary goals of 
ARV treatment are maximal and persistent suppression of viral load, restoration 
and preservation of immunologic function, improvement of quality of life, and 
reduction of HIV-related morbidity and mortality (Department of Health, 2003).  
When taking ARV therapy, a patient should experience fewer HIV-related illness, 
his/her CD4 cell count should rise and remain above the baseline count, and the 
patient’s viral load should become undetectable (<400 copies per mm3) and 
remain undetectable (Grimwood, 2004).  ARV therapy also leads to substantial 
body mass gain (Grunfeld et al., 1992).  It has been demonstrated that 
combination ARV therapies significantly delay the progression of HIV and 
improve survival (Smith et al., 2001).  However, HIV mutates rapidly and can 
become resistant to drugs but this is less likely to happen when combinations of 
different classes of ARV drugs, known as highly active antiretroviral therapy 
(HAART) are used (Griffen, 2003; Stringer et al., 2001).  HAART is usually 
initiated when viral load rises late in the course of infection.   
 
The Department of Health (2003) has set criteria which have to be met before 
ARV treatment can be initiated in adults.  These criteria include: 
• CD4 cell count < 200 cells per mm3 and symptomatic, irrespective of stage, or 
• WHO stage IV AIDS defining illness, irrespective of CD4 cell count, and 
• Patient prepared and ready to take ARVs adherently. 
   
The provision of ARV drugs in developing countries such as South Africa has 
been limited because of a number of factors, most importantly the high cost of 
these medications (Stewart et al., 2004).  The choices of ARV regimes are limited 
because of the limited availability of approved drugs in South Africa and resource 
restrictions.  Two regimes are recommended for use in the South African public 
sector (Grimwood, 2004).  Table 1.2 shows the regimes followed in South Africa.   
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Each regime consists of one or more nucleoside reverse transcriptase inhibitors 
(NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease 
inhibitors (PI) (Safrin, 2001).  NRTIs act by competitive inhibition of HIV-1 
reverse transcriptase and can also be incorporated into the growing viral DNA 
chain and cause termination of the viral DNA.  NRTI drugs include Zidovudine 
(AZT), Didanosine (ddI), Lamivudine (3TC) and Stavudine (d4T).  NNRTIs bind 
directly to a site on the viral reverse transcriptase that is near to but distinct from 
the binding site of NRTIs.  The binding of NNRTIs to the enzyme’s active site 
results on the blocking of RNA- and DNA-dependent DNA polymerase activities.  
NNRTIs include Nevirapine (NVP) and Efavirenz (EFV).  Protease Inhibitors (PI) 
prevent new waves of infection by preventing the production of mature infectious 
virions during HIV replication.  Ritonavir and Lopinavir are examples of PIs.  
Each drug used in the treatment regimes of HIV is discussed in more detail below. 
 
Table 1.2 Antiretroviral (ARV) Treatment Regimes used in South Africa. 
Regime Drugs Indications 
1a  
First line regime 
Stavudine (d4T) 
Lamivudine (3TC) 
Neverapine  
• Men 
• Women of childbearing 
potential 
• Pregnant women  
• Conditions where 
Efavirenz is 
contraindicated 
1b 
Alternate first line 
regime 
Stavudine (d4T) 
Lamivudine (3TC) 
Efavirenz 
• Persons who develop 
Neverapine intolerance 
• Persons who have evidence 
of hepatoxicity 
• Other conditions where 
Neverapine is 
contraindicated 
2 
Second line regime  
Zidovudine (AZT) 
Didanosine (ddI) 
Lopinavir 
Ritonavir 
• Persons who ‘fail’ regime 
1a or 1b 
• First line in patients who 
have evidence of 
Neverapine resistance 
before ARV initiation 
Adapted from Department of Health, 2003: Operational Plan for Comprehensive HIV and AIDS 
Care, Management and Treatment for South Africa.  Department of Health, South Africa. 
Patients with advanced HIV disease, particularly those with a CD4 cell count of 
less than 50 cells per mm3, may become ill with an immune reconstitution illness 
during the first few weeks of ARV use (Grimwood, 2004).  Immune 
reconstitution illnesses occur when an improving immune function reveals a 
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previously latent opportunistic infection i.e., an infection that was present in the 
patient’s body but was not clinically evident.  They may have signs and symptoms 
of sweats, loss of body mass, cough, persistent fever and shortness of breath.  TB 
is a common immune reconstitution illness in South Africa.  However, immune 
reconstitution illnesses are not indicative of drug failure or drug side effects, and 
ARV treatment should be continued. 
 
A patient’s best chance of a good clinical outcome is when the first line treatment 
is successful.  A second line regimen, while still being effective, is often less 
effective than the first line, as the virus may have developed resistance to a 
specific class of drugs (Department of Health, 2003).  Development of resistance 
to a specific ARV agent may result in resistance to other drugs within the same 
class and can significantly limit future treatment options (Stewart et al., 2004).  If 
the second line of drug treatment fails, then salvage therapy, which is a highly 
specialized and expensive treatment, may have to be considered.  Salvage therapy 
is not currently available in the South African public sector because of the high 
cost and limited clinical benefit. 
  
Use of ARV therapy usually results in a reduction of viral load to undetectable 
levels and an increase in CD4 cell counts, with a concomitant restoration of 
immune competence (Griffen, 2003).  Suppression of HIV replication plays an 
important role in prolonging life as well as improving the quality of life of 
patients with HIV infection (Fauci et al., 1994).  HAART has been associated 
with a reduction in the severity of body mass loss and malnutrition and an 
improvement in the immune status of HIV positive patients (O’Brien et al., 2005).  
ARV therapy has resulted in dramatic decreases in the mortality and morbidity 
from HIV infection (Stringer et al., 2001).  There is a increased prevalence of 
persons living with HIV disease, primarily as a result of improvements in ARV 
therapy and subsequently fewer opportunistic infections (Clingerman, 2003).  As 
a result, more consideration must be given to the long-term health of individuals 
infected with HIV, especially because HIV infection and treatment may increase 
the risk of other common diseases such as heart disease, diabetes and 
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hypercholesterolemia (Stringer et al., 2001).  However, there is also the risk of 
drug toxicity and the development of drug resistance to ARV therapy.  Therefore, 
the HIV positive patient can consider complimentary therapies, such as exercise 
and nutrition, to maintain the integrity of his/her immune system should drug 
toxicity develop. 
  
Aside from the positive effect of slowing HIV disease progression, ARV therapy 
has been associated with troubling symptoms such as fatigue, dyspnoea (shortness 
of breath) and undesirable body mass change (Smith et al., 2001).  A new set of 
metabolic and body composition abnormalities have arisen in HIV infected 
patients, in association with ARV therapy (Hellerstein, 2001; Jones et al., 2001; 
Stringer et al., 2001).  Metabolic dysregulation, such as lipodystrophy 
(lipohypertrophy and lipoatrophy), a condition associated with abnormal fat 
distribution as well as glucose intolerance, diabetes mellitus and hyperlipidemia 
are more common in patients who are on HAART, as well as a syndrome that 
includes lactic acidosis which may reflect tissue mitochondrial toxicity 
(Hellerstein, 2001).   
 
Although HAART has been known to reduce the severity of body mass loss, it 
may also be associated with unwanted changes in body composition known as 
lipodystrophy (O’Brien et al., 2005; DoH, 2004; Grimwood, 2004). 
Lipodsytrophy is a syndrome associated with physical and metabolic changes in 
the body and is characterized by a reduction in subcutaneous fat in the face, arms, 
legs and buttocks, and an increase in visceral fat in the abdomen, back of neck 
and breasts.  Lipohypertrophy is the deposition of fat just behind the neck 
(“buffalo hump”) or visceral abdominal fat deposition.  Conversely, lipoatrophy 
may occur with loss of adipose tissue in the face, arms or legs.  Lipohypertrophy 
and lipoatrophy may be observed in the same patient.  Plasma triglyceride 
concentrations are elevated in patients with AIDS and somewhat elevated in HIV 
positive patients (Grunfeld et al., 1992), and is thought to be due to slowing of 
triglyceride clearance.  Many of these abnormalities in lipid metabolism may act 
as risk factors for coronary artery disease (Jones et al., 2001).  Lipid abnormalities 
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(dyslipidemia) are primarily reported with the use of PIs but have also been 
reported with the usage of NRTIs and NNRTIs (DoH, 2004; Grimwood, 2004).  
Increases in total cholesterol are usually due to administration of PIs.  NNRTIs 
are also known to increase total cholesterol but have also been reported to 
increase high density lipoproteins (HDL), particularly Efavirenz.  Lifestyle 
modifications such as increased PA levels, proper nutrition and body mass loss 
have been recommended by the DoH as important measures to prevent or 
decrease lipid abnormalities (DoH, 2004; Grimwood, 2004). 
 
HIV infection and PI treatment are associated with impaired lipid metabolism, 
including elevations in triglycerides and cholesterol, similar to the changes 
observed with type 2 diabetes in individuals who are not HIV infected (DoH, 
2004; Cade et al., 2003; Hellerstein, 2001; Stringer et al., 2001).  Impaired 
glucose metabolism, such as glucose intolerance, has been associated with PI 
treatment, and the degree of insulin resistance has been significantly associated 
with the degree of lipodystrophy (Cade et al., 2003; Stringer et al., 2001).  
 
Gastrointestinal or abdominal discomfort is the most commonly reported ARV 
side effect and may occur earlier on in therapy (DoH, 2004).  Common 
complaints include abdominal discomfort, nausea and vomiting, loss of appetite, 
diarrhoea, abdominal pain, pancreatitis, constipation and heartburn. 
 
The use of NRTIs is also reported to be associated with distal symmetric 
polyneuropathy (Department of Health, 2004).  Distal symmetric polyneuropathy 
is characterized by injury or loss of primary afferent fibers, resulting in distal 
axonal degeneration (Verma et al., 2005), and usually presents with distal 
symmetric distribution and sensorimotor paralysis.  Numbness or burning 
dysesthesia of the distal extremities occurs at times with sharp, shooting pains or 
continuous severe burning.  These symptoms of distal symmetric polyneuropathy 
can lead to gait difficulties and sleep disturbances, which may have a significant 
impact on quality of life.  The pain may become so severe that patients develop 
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contact sensitivity to bed sheets or socks or feel sensations of pain when touched 
by non-painful stimuli e.g., cotton wool, a condition known as allodynia. 
 
Abnormal patterns of gaseous exchange have been noted in HIV positive patients, 
resulting in reduced exercise capacity (Pothoff et al., 1994).  HAART has been 
known to disrupt normal mitochondrial functions, by causing pathological 
changes in mitochondrial structure (mitochondrial swelling, cristae disruption) 
and damaging and decreasing the number of mitochondrial DNA and RNA.  The 
use of NRTIs also results in a deficiency of specific mitochondrial enzymes 
essential for ATP production via oxidative phosphorylation (Cade et al., 2004).  
Delayed recovery and larger depletion of phosphocreatine following muscular 
exercise have also been reported with NRTI use.  These alterations in 
mitochondrial function may be a contributor to muscle oxygen extraction-
utilization limitation in most individuals treated for HIV infection (Cade et al., 
2003).  It is this muscle oxygen extraction-utilization limitation that has been 
identified as a mediator of diminished aerobic capacity and would likely limit 
participation in physical activity.   
 
Lactic acidosis is a rare but life threatening condition and usually occurs in one to 
20 months after the start of NRTI therapy (Department of Health, 2004).  Clinical 
symptoms are not specific and include fatigue, nausea, vomiting, abdominal pain, 
body mass loss and dyspnea.  These symptoms may occur acutely or gradually 
over time. 
 
The recognition of these new adverse effects associated with ARV therapy 
requires health care professionals to pursue more aggressive symptom 
management strategies (Smith et al., 2001).  The pharmacological approach to 
symptom management in HIV patients is not without risk.  Patients may not wish 
to add other medications to an already complex regime.  Therefore, there is a need 
for alternative strategies to manage the disease as well as the adverse effects 
associated with ARV use.  It may be considered more appealing to use alternative 
therapies than conventional medical treatment that is often perceived as 
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unpleasant, and even toxic (Singh et al., 1996).  Therefore the popularity and use 
of nontraditional therapies among patients with HIV infection has grown 
enormously. 
  
Scientific advances are occurring at an extremely rapid pace in the area of HIV 
research, especially with regards to treatment of opportunistic diseases, and 
vaccine development (Fauci et al., 1994; Chlebowski et al., 1989).  Despite these 
advances, the HIV pandemic is growing in magnitude world wide and the cost in 
human life and suffering is staggering (Fauci et al., 1994).  Even with the 
development of HAART, the pandemic is confounded by socioeconomic factors 
and unequal access to health care (Brown et al., 1997).  Physicians and other 
health care workers are in the unusual position of caring for HIV-infected 
individuals within the framework of a rapidly evolving scientific and clinical 
discipline.  Therefore, physicians and health care workers are continually 
implementing alternative therapies, such as physical activity (PA) and exercise, 
lifestyle modifications and nutrition, as a strategy to manage the disease.  With 
the role of HAART in prolonging the life of HIV-infected individuals, HIV is 
being increasingly referred to as a chronic disease, and both drug and non-drug 
therapies should be offered to mitigate the long term risk of the metabolic 
complications of HIV and HAART. 
 
1.1.6 Physical Activity and HIV 
For most people who are able to access and tolerate HAART, HIV has become a 
chronic condition characterized by cycles of illness and wellness, which has led to 
a potential increase in the prevalence and impact of disability of people living 
with HIV infection (O’Brien et al., 2005).  Persons living with HIV disease 
experience a range of disease impacts.  These impacts include limitations in 
physical and role functioning i.e., the ability to perform physical activities without 
assistance or to carry out social roles such as employment (Crystal et al., 2000).  
Functional ability (or the restriction of it) is a major factor in determining if a 
person is capable of independent living (Mathie et al., 2004).  A person’s level of 
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functional ability has a significant impact on quality of life.  Individuals infected 
with HIV are living longer lives compared to similar populations in history, but 
with physical, psychological and social challenges, which all affect quality of life 
(Rusch et al., 2004).  HIV disease can deprive an individual of his or her physical 
resources, such as mobility, muscular strength, joint flexibility, endurance and 
energy (Clingerman, 2003).  There is a high prevalence of fatigue and lack of 
endurance in HIV positive patients, many of whom face challenges with daily 
activities (Rusch et al., 2004).  It has been established that HIV infection 
compromises pulmonary function even in the early stages of the disease (Pothoff 
et al., 1994), which may be a contributing factor to the fatigue experienced by 
HIV positive patients.   Alternative strategies for the management of HIV-
infection and its related metabolic syndromes need to be considered because of 
the changing course of HIV.  A number of non-nutrient based strategies, such as 
physical activity and exercise, are available to physicians for improving 
endurance and increasing lean body mass, and thus functional status, in HIV 
infected individuals (Hellerstein, 2001).  
 
Physical activity (PA) may help manage HIV-related stress and improve aerobic 
capacity and cardiopulmonary and immune function in HIV positive patients.  
Physical activity (PA) is defined as any bodily movement produced by the 
skeletal muscles resulting in energy expenditure (EE), in the form of heat loss, 
above the resting levels (Shepard, 2003; Meijer et al., 1991; Casperson et al., 
1986).  Physical activity (PA) has both physiological and behavioural aspects 
(Baranowski et al., 1992).    From a physiological perspective, PA is a component 
of total EE, which also includes resting EE, energy expended with food digestion 
and growth.  From a behavioural perspective, PA can be viewed within several 
frameworks, e.g., recreational, rehabilitative, developmental or health related.   
 
Of the most relevant interest is habitual PA i.e., activity that is performed on a 
daily basis, and is composed of the following domains: leisure time, gardening or 
yardwork, household chores, transport or moving from place to place, and 
occupational physical activity (Booth, 2000).  High levels of habitual PA are 
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considered an essential component of a healthy lifestyle (Ridgers et al., 2005; 
Hardman, 1999).  Regular participation in moderate PA is an essential component 
of a healthy lifestyle (Padden, 2002).  Moderate PA enhances immunity (by 
increasing CD4 cell counts or by slowing CD4 cell count decline) and may even 
lower the risk of some infections (Mustafa et al., 1999; Mackinnon, 1994).  For 
patients with metabolic syndrome, increasing PA is encouraged (Wigle, 2006). 
PA has the potential to improve the body composition of HIV positive patients 
suffering from HIV related lipodystrophy (Roubenoff et al., 1999).  High levels of 
habitual PA positively influence a number of conditions including osteoporosis, 
obesity, hypertension and diabetes (Blair, 1993).  Since functional status and well 
being are highly valued by patients with chronic conditions (Stewart et al., 1989), 
PA may contribute to the maintenance of functional status and improvement in 
the physical and mental well-being of people infected with HIV.  Psychological 
benefits of PA include positive changes in mood, relief from tension, depression 
and anxiety, and increased ability to mentally cope with daily activities (Padden, 
2002).   
 
1.1.7 Exercise as a subcategory of physical activity 
As mentioned above, PA is defined as any bodily movement produced by skeletal 
muscles that result in energy expenditure (EE).  However, exercise is a 
subcategory of PA and is defined as planned, structured movement undertaken to 
improve or maintain one or more aspects of physical fitness (Shepard, 2003; 
Casperson et al., 1986).  Exercise is one fundamental management strategy used 
by health care professionals to address impairments, activity limitations and 
participation restrictions in the HIV positive population (O’Brien et al., 2005).  
Exercise is considered an attractive option because it is inexpensive (Bhasin et al., 
2000), and it is known that exercise is an effective method used to reduce risk 
factors and morbidity of cardiovascular and other chronic diseases as well as to 
improve mental health (Jones et al., 2001; Mustafa et al., 1999).  Exercise is also 
used to address unwanted changes in body mass and body composition in HIV 
positive people (O’Brien et al., 2005) by either maintaining muscle mass 
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associated with HIV infection or by preventing abnormal fat distribution caused 
by ARV use.     
 
Long term survivors of HIV infection have attributed their longevity to various 
lifestyle modifications, including changing exercise habits (Eichner et al., 1994).  
The Department of Health’s Operational Plan for Comprehensive HIV and AIDS 
Care, Management and Treatment for South Africa (2003) states that HIV 
positive patients who are early in the course of their infection will benefit 
primarily from good nutrition, stress reduction and behavioural modification.  
Increasing PA and exercise levels as part of this behavioural modification can 
maintain the quality of life of these patients as well as contribute to stress 
reduction.  Combined aerobic and resistance exercise has been suggested to 
contribute to the modification of blood lipid concentrations, preventing the 
deposition of fat (Jones et al., 2001).   It has also been shown that performing 
constant or interval aerobic exercise, or a combination of aerobic and progressive 
resistance exercise interventions at least three times per week for at least four 
weeks appeared to be safe and may lead to clinically important improvements in 
cardiopulmonary fitness, body body mass and composition for medically stable 
HIV positive adults (O’Brien et al., 2005).  Improvement in muscle strength and 
flexibility, cardiopulmonary function, decrease in depression, anxiety and anger, 
and increase in CD4 cell count following exercise training in HIV infected 
individuals has been reported (Mustafa et al., 1999).  Exercise may therefore be 
associated with slower HIV disease progression as well as improved mental well 
being, and may prove to be an important adjunctive therapy in future HIV disease 
management (Mustafa et al., 1999). 
 
Submaximal aerobic exercise is used as a therapy to improve functional status and 
stimulate the immune system in HIV-infected individuals.  Aerobic exercise has 
been used in managing signs and symptoms of other chronic illnesses and is 
widely used in health promotion and rehabilitation programmes to improve 
physical endurance (Smith et al., 2001).  Therefore, aerobic exercise may be an 
effective alternative in the treatment of certain signs and symptoms associated 
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with HIV infection.  HIV-infected individuals who have participated in aerobic 
exercise programmes have demonstrated improved aerobic capacity, functional 
status, lean body mass, body mass, mood and quality of life (Stringer et al., 2001). 
 
Aerobic exercise has been shown to have no harmful effects on the immune 
system of an HIV infected individual (Stringer et al., 2001).  The changes 
observed with immune function were small and not clinically significant.  
However, the lack of detrimental effect is important.  Therefore regular aerobic 
exercise can be recommended without hesitation as an important complimentary 
therapy. 
 
Although aerobic exercise has been shown to improve the functional capacity of 
HIV-infected individuals, it is not associated with substantial skeletal muscle 
hypertrophy (Zinna et al., 2003).  Aerobic exercise primarily alters the enzyme 
activity of mitochondrial and cytosolic proteins while resistance exercise is 
responsible for increasing contractile protein mass.  Therefore, resistance exercise 
is combined with aerobic exercise to improve muscle size and strength of HIV-
infected individuals. 
 
Resistance exercise is used as a medical therapy to increase lean body mass 
(Hellerstein, 2001).  Progressive resistance exercise is a type of exercise that 
involves strengthening of muscle tissue that may include, but is not limited to 
activities such as isotonic strengthening exercises, and isometric strengthening 
exercises (O’Brien et al., 2005).  
  
Resistance exercise has been associated with significant gains in muscle strength, 
size and body body mass, counteracting the effects of AWS and cachexia in HIV-
infected individuals (Bhasin et al., 2000).  Pharmacological interventions of 
anabolic agents such as testosterone supplementation have received attention 
(Hellerstein et al., 1990).  Such supplementation has been shown to improve 
muscle mass and strength (Bhasin et al., 2000).  However, the effects of 
testosterone interventions and resistance exercise were not additive, indicating 
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that resistance exercise can be as effective, but much less expensive with fewer 
side effects, as testosterone supplementation in managing the muscle wasting and 
loss of strength associated with HIV infection (O’Brien et al., 2005; Bhasin et al., 
2000).  Progressive resistance exercise interventions, with or without aerobic 
exercise also contribute to improvements in psychological status for HIV positive 
adults (O’Brien et al., 2005). 
  
Exercise has been known to reduce risk factors and morbidity of cardiovascular 
and other chronic diseases as well improve mental health.  In general, exercise has 
been shown to improve muscle strength and flexibility, cardiopulmonary function, 
decrease depression, anxiety and anger, and increase CD4 lymphocytes (Mustafa 
et al., 1999).  The stress of a positive HIV test and living with HIV has been 
shown to alter immune function and exercise training has been suggested to 
attenuate some of the psychological and immunological effects of this stress 
(Eichner et al., 1994).  LaPerriere et al. (1994) and Jonsdottier et al. (1997) 
suggest that exercise training reduces depression and anxiety, increases the 
release of endogenous opiates (endorphins) and decreases stress hormone levels, 
and normalizes the immune system as a result of increased number and function 
of natural killer cells and lymphocytes.  The endorphins are also associated with 
improved pain tolerance and mood state (Schwarz et al., 1992) indicating that 
exercise can be used in the management of HIV related pain.  It has also been 
shown that HIV infected people who participate in regular exercise have a more 
positive perception of their health than those who do not participate regularly 
(Munro et al., 1998).  Therefore, exercise training has been implied to be 
beneficial from both a psychological and immunological perspective (Eichner et 
al., 1994).  Exercise, especially moderate activity, may be associated with slower 
HIV disease progression, and may prove to be an important supportive therapy in 
HIV disease management (Mustafa et al., 1999). 
A regime of combined aerobic and resistance training can be effective in 
enhancing functional capacity (strength and aerobic endurance), reducing 
subcutaneous fat, total cholesterol, triglyceride concentrations and increasing 
body mass (Jones et al., 2001).  The usefulness of exercise additional to 
 21
conventional HAART may rest on its potential to decrease the body composition 
and lipoprotein disturbances associated with adherence to HAART. 
 
A holistic approach to treating and living with HIV and AIDS, including ARV 
treatment, as well as lifestyle modification (increased PA and exercise levels, and 
improved nutritional status), is a key factor for success in living a longer, 
healthier life with the disease.  The health benefits of PA and exercise in the 
management of HIV are well documented.  However, it is unknown if people 
infected with HIV are currently participating in these health promoting PA 
behaviours in order to better manage the disease.  The role of PA epidemiology 
therefore becomes more important.  The descriptive epidemiology of PA as an 
individual behaviour provides insights into the types and amounts of PA 
performed by members of a population (Casperson, 1989).  Therefore, physical 
assessment techniques should be employed in order to better understand the type, 
frequency and duration of PA undertaken by HIV infected individuals.  It is this 
information that contributes to the development, implementation, and evaluation 
of policy designed to promote a more active and healthy society (Dominguez-
Berjon et al., 1999; Bernstein et al., 1998; Casperson, 1989). 
 
1.1.8 Physical Activity Assessment Techniques 
Assessment of habitual physical activity (PA) is an imperative task to determine 
descriptive information about different populations (Iltis et al., 2000).  
Measurement of PA needs to include accurate estimates of energy expenditure 
(EE) and the ability to determine the manner in which an individual expends 
energy during the day (Matthews et al., 1995).  The assessment of habitual PA 
behaviours of a specific population, however, is challenging, because people are 
active in different ways, at different times, at many locations, and for different 
reasons (Sallis et al., 1985).  PA is based on individual habits and the pattern of 
activity among individuals varies based on the day, week or time of year 
(Freedson et al., 2000; Sallis et al., 1985).   It is also a difficult behaviour to 
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assess because it involves several variable aspects such as type, intensity, duration 
and frequency (Brage et al., 2003; Sallis et al., 1985). 
   
Some of the most commonly used methods to estimate PA and EE are recall 
questionnaires, activity diaries, interviews, direct observations and time-motion 
analysis, heart rate monitoring, movement sensors, and direct and indirect 
calorimetry (Ramirez-Marrero et al., 2005; Montoye, 2000; Bernstein et al., 
1998).  The selection of a measurement approach depends on the purpose of the 
study (Tudor-Locke et al., 2001). 
 
PA questionnaires are currently the most practical and widely used method for the 
assessment of PA in epidemiologic research (Tudor-Locke et al., 2001; Bernstein 
et al., 1998; Aaron et al., 1995; Washburn et al., 1990) because of their ease of 
administration and distribution.  They require no technical equipment, are less 
expensive and do not interfere with subjects’ usual activity.  PA questionnaires 
are generally retrospective and require recall of specific activities over a specific 
time frame.  The information gained from the questionnaire is converted to an 
estimate of caloric expenditure (Tudor-Locke et al., 2001) or multiples of the 
average resting metabolic rate (METS) (Shepard, 2003; Ainsworth et al., 2000; 
Lamb et al., 1990).  A MET is defined as the ratio of work metabolic rate to a 
standard metabolic rate of 1.0 (4.184kJ per kg per hr).  Therefore, 1 MET is 
considered a resting metabolic rate obtained during quiet sitting.  However, care 
must be taken when interpreting MET scores, because increments of energy 
expenditure may not be uniform across all populations (Shepard, 2003).  
Although METS (multiples of average resting metabolic rate) will be the same 
across all populations, conversion into EE (according to Ainsworth et al., 2000) 
for comparitive purposes between HIV positive and HIV negative populations 
will be invalid because HIV positive patients are hypermetabolic, and have a 
significantly higher resting EE (Macallan et al., 1995; Suttman et al., 1993; 
Grunfeld et al., 1992; Hellerstein et al., 1990).  Therefore, more research into this 
field is required.   
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A limitation of using a questionnaire to assess PA is that questionnaires are 
subjective in nature.  Self report of PA is susceptible to inaccuracy and/or 
imprecision as these instruments are dependent on subjects’ ability to recall or 
report PA (Freedson et al., 1998).  Subjects are likely to recall vigorous, 
structured activity with a high degree of accuracy, but are not as good at recalling 
frequent, moderate intensity activities such as walking (Basset et al., 2000).  It has 
been suggested that activities such as walking are the major contributors to PA in 
normal life, as most people spend a large amount of time walking for their work 
or for leisure activities (Levine et al., 2001; Terrier et al., 2001; Meijer et al., 
1991).  An inability to accurately recall such activities would result in inaccurate 
quantification of PA.  Another limitation with this method of PA assessment is 
that reporting of PA performed may be influenced by the perceived desirability of 
a given response (Klesges et al., 1990) as well as inaccurate perception of one’s 
activity behaviour (Freedson et al., 2000).  Most individuals overestimate their 
PA when left alone to determine their level of exertion in specific activities 
(Conway et al., 2002).  A third limitation is that lifestyle activity is generally less 
structured than more vigourous bouts of exercise and therefore may be harder to 
code and recall on self-report instruments (Welk et al., 2000).  Lifestyle activities 
also encompass a wide range of intensities, and can also be accumulated 
throughout the day, making it difficult to obtain an accurate measure of the 
amount, intensity or duration of activity.  Hence there are difficulties associated 
with addressing frequency, intensity and duration of lifestyle activity. 
 
Questionnaires are practical for obtaining data on large samples and are therefore 
well suited to surveillance and screening (Tudor-Locke et al., 2001).  However, to 
eliminate many problems associated with self-report measures, it is necessary to 
explore alternative methods that do not rely on the individuals’ ability to recall 
activity or on the quality of the questionnaire (Freedson et al., 1998).  Motion 
sensors, such as accelerometers, have the potential to eliminate these problems 
and offer the most promise for precisely quantifying PA behaviour. 
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Advances in technology have generated an increased interest in objective 
monitoring of PA using body worn motion sensors or activity monitors, for 
example, accelerometers and pedometers (Le Masurier et al., 2003; Hendelman et 
al., 2000).  Activity monitors were developed in response to the lack of reliability 
of self-report measures such as questionnaires and activity diaries, the 
intrusiveness of direct observation, and the complexity of heart rate monitoring 
(Puyau et al., 2002).  Objective monitoring of physical activity by activity 
monitors is now supported by technology that is capable of capturing free-living 
PA information (Mathie et al., 2004; Tudor-Locke et al., 2002), and allows for the 
continuous and precise measurement of PA intensity (Brage et al., 2003).  An 
activity monitor is an electronic instrument that picks up motion or acceleration of 
a limb or trunk, depending on where the monitor is attached to the body (Freedson 
et al., 2000).  Every movement requires acceleration and deceleration of the trunk 
or body segments.  An activity monitor records acceleration changes to evaluate 
EE as well as the amount of PA performed.  The activity monitor will best 
measure human motion (and estimate EE accurately) when the monitor is attached 
to the body part responsible for the motion and optimally aligned with the motion 
itself (Heil, 2006).  Under free-living conditions, activity monitors attached to the 
ankle or wrist are probably far more likely to record motions not relating to the 
activity being performed (e.g. fidgeting).  Therefore, the most common site for 
activity monitor placement is on the hip. 
 
An activity monitor allows for the assessment of movements of the body in order 
to get a quantitative measure of physical activity (Meijer et al., 1991).  The most 
common commercially available activity monitors can be described as uniaxial 
(sensing motion in a single plane), or triaxial (sensing motion in all three planes) 
(Heil, 2006).  However, the Actical® (Mini Mitter Company Inc, Oregon) activity 
monitor is described as omnidirectional that is most sensitive in a single plane and 
less sensitive in other planes.  As a result, these devices have the ability to detect 
concurrent activity data, expressed as activity counts on a minute-by-minute basis 
for weeks at a time with minimal intervention from the researcher (Metcalf et al., 
2002; Tudor-Locke et al., 2002; Basset, 2000).  These activity counts are the 
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result of duration, frequency and intensity of movement, sampled at set intervals 
(Heil, 2006; Mathie et al., 2004; Powell et al., 2003; Puyau et al., 2002; Tudor-
Locke et al., 2001; Eston et al., 1998).  The capacity to store activity counts over 
small time periods permits the evaluation of patterns of activity within a day or 
over several days (Freedson et al., 1998). 
 
Activity monitors have been validated against indirect calorimetry and calibrated 
in terms of resting metabolism equivalents (METS) (Puyau et al., 2002).  METS 
per minute is a useful measure as it emphasizes movement, independent of body 
size (Jacobs et al., 1993).  It further emphasizes that interpretation of amount of 
PA in kilocalories per day, or kilocalories per kilogram body mass per day 
includes assumptions of the relation of EE to body size.  However, variation in the 
estimate of resting metabolic rate is not taken into account.  As discussed above, 
conversion of METS obtained from the PA monitoring by activity monitors of 
HIV positive patients, into EE, will be incorrect due to the higher resting EE in 
the HIV positive population (Macallan et al., 1995; Suttman et al., 1993; Grunfeld 
et al., 1992; Hellerstein et al., 1990).  However, these activity monitors can be 
used to monitor parameters that are sensitive to changes in health or functional 
status, by monitoring the amount of hourly and daily physical activity and the 
amount of time spent resting during the day and at night (Mathie et al., 2004). 
 
The small size, ease of use and objectivity of activity monitors make them a 
promising tool to assess PA and EE (Swartz et al., 2000).  They provide a 
convenient tool for assessing PA outside the laboratory setting in a free living 
environment: they are relatively simple to use, unobtrusive by not impeding 
movement, compatible with most daily activities and are well tolerated by 
subjects, allowing for little subject influence (Mathie et al., 2004; Welk et al., 
2004; Freedson et al., 2000; Hendelman et al., 2000; Fehling et al., 1999; 
Sequeira et al., 1995). 
 
A limitation of activity monitors is that they are unable to detect the metabolic 
cost associated with standing, upper body movements, static work, vertical lift 
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and changes in gradient (Basset, 2000).  Also, if the activity monitors are 
positioned or angled in slightly different ways when taken off and reattached to 
the body, a measurement error occurs (Welk et al., 2004).  These differences are 
likely when monitors are worn under free-living conditions as it is harder to 
standardize positions on the hip and maintain proper orientation of the monitor 
during field-based monitoring over several days. 
 
Therefore, the best option for objectively monitoring physical activity is to use a 
combination of indirect and direct assessment techniques i.e. using a self-report 
questionnaire in conjunction with an accelerometer. 
 
1.1.9 Summary 
Early on in the HIV disease process, individuals may appear physically 
asymptomatic yet may experience psychosocial symptoms such as sadness, stress, 
anxiety, and fear.  As HIV disease progresses in severity and symptoms increase, 
individuals face multiple lifestyle changes and eventual debilitation.  People 
living with HIV experience high levels of depression, body impairments, activity 
limitations and participation restrictions.  Physical inactivity places all people, 
including persons living with HIV disease, at a higher risk for other acute and 
chronic conditions and can prevent them from achieving their highest level of 
wellness.  Developing and maintaining a healthy lifestyle can help counteract the 
negative effects of HIV disease.  However, little is known about current health 
promoting PA behaviours of people living with HIV disease.  Type, frequency 
and duration of PA behaviours for this specific population are absent in the 
empirical literature.  Also, previous studies have focused on the immunological 
response of people infected with HIV rather than on how HIV infection impacts 
on their ability to exercise or perform various types of PA.  This study focused on 
identifying the association between HIV infection and habitual PA behaviours, 
functional independence and exercise capacity in a group of HIV positive adults 
who were either taking ARV medication or who were not taking ARV 
medication.  The results of this study can be used in the development, 
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implementation, and evaluation of health policies which outline specific 
interventions to promote a more active and healthy HIV positive population. 
 
1.2 Aims of Study 
The aim of this study was to determine the impact of HIV infection on the 
habitual physical activity levels, functional independence and exercise capacity, 
in a group of HIV positive South African adults either taking or not taking 
antiretroviral medication.   
 
 The objectives of the study were: 
a) To assess the relationship between CD4 cell count (a marker of HIV 
disease progression), habitual physical activity levels and functional 
independence in an HIV positive South African adult population either 
taking or not taking antiretroviral medication. 
b) To compare the aerobic capacity, lower limb muscle strength, handgrip 
strength and physical activity count of age-matched HIV negative black 
females and HIV positive black females who are taking antiretroviral 
medication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 – Materials and Methods 
 
2.1 Introduction 
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The purpose of this study was to determine the impact of HIV infection on the 
habitual physical activity levels, functional independence and exercise capacity, 
in a sample of HIV positive South African adults either taking or not taking 
antiretroviral (ARV) medication.  Therefore the study was composed of two parts.  
Firstly, a Lifestyle and Physical Activity questionnaire was used to determine the 
relationship between CD4 cell count, habitual physical activity levels and 
functional independence in a group of HIV positive outpatients either taking or 
not taking ARV medication.  Secondly, a group of HIV positive female 
outpatients, who were taking ARV medication, and a group of HIV negative age-
matched control subjects completed a physiological exercise testing protocol 
which assessed their aerobic capacity, lower limb muscle strength, handgrip 
strength and physical activity counts. 
 
2.2` Lifestyle and Physical Activity Questionnaire 
2.2.1 Patients 
A total of 200 HIV positive outpatients from the antiretroviral roll out site at 
Helen Joseph Hospital (Auckland Park, Johannesburg) were approached to 
complete a Lifestyle and Physical Activity Questionnaire.  This was considered a 
convenient sample as these patients regularly present themselves at the clinic for 
monthly check ups and to receive treatment if needed.  As the majority of the 
patients completing the questionnaire were black, the nine patients who were 
Caucasian or coloured were excluded as this sample did not have any sample 
power.  One scholar was also excluded due to her age.  The data from four 
questionnaires were not used as CD4 cell counts were not available.  Therefore, 
the data from one hundred and eighty six black male (n=47) and female (n=139) 
HIV positive outpatients were used to assess the current habitual PA levels in this 
population.  The gender imbalance is representative of the patient demographics 
at this clinic.  The patients were between 20 and 60 years of age (35.2 ± 7.9; mean 
± SD).  The experimental protocol was approved by the University of the 
Witwatersrand Committee for Research on Human Subjects (Protocol Number 
M050525; Appendix A).  All patients gave written consent before completing the 
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questionnaire.  Two multilingual interviewers assisted patients in completing the 
questionnaire correctly.  The questionnaire was completed anonymously, with 
reference numbers being used for identification purposes. 
 
2.2.2 Questionnaire 
The questionnaire used in this study assessed the habitual physical activity levels 
of HIV positive black South African adults (Appendix B).  The questionnaire was 
developed from three previously validated questionnaires namely the Modifiable 
Activity Questionnaire (Kriska et al., 1990), Minnesota Leisure-Time Physical 
Activity Questionnaire (Taylor et al., 1978) and the Baecke Questionnaire of 
Habitual Physical Activity (Baecke et al., 1982).  The questionnaire was divided 
into six sections.  Section A contained questions regarding the patient’s 
demographic information, including gender, age, race and home language, as well 
as socioeconomic information, including employment status, income, education, 
residence and amenities available in his/her residence.  Section B gathered 
information about the patient’s HIV status and included questions regarding 
diagnosis, current CD4 cell count, if and what antiretroviral medication was used 
and for how long, side effects from medication since commencement of ARV 
treatment and the occurrence of opportunistic infections in the past 12 months.  
Section C dealt with the patient’s inactivity, by determining the level of 
independence of each patient as well as energy used in inactive situations, such as 
sleeping and watching television.  Section D contained questions regarding the 
patient’s activity levels in his/her occupation.  This section was not completed if 
the patient was unemployed.  Section E gathered information about the physical 
activity levels within the patient’s household, and required the patient to 
determine the length and frequency that specific domestic duties were performed 
in his/her house.  Section F of the questionnaire dealt with physical activity from 
a recreational perspective, independent of occupation and housework.  The patient 
was required to recall the length and frequency of certain recreational activities. 
 
From the questionnaire, a metabolic equivalent (MET) which is a proxy for the 
intensity level of physical activity performed in the last month was calculated 
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(Ainsworth et al., 2000).  The number of hours accumulated each day for a 
specific activity was multiplied by the number of times each activity was 
performed in one week.  Hours per week were multiplied by 4.3 weeks in order to 
determine the number of hours each activity was performed per month.  The result 
obtained was multiplied by the metabolic cost of the activity expressed as a 
multiple of one resting MET (one MET is defined as the metabolic cost of sitting 
quietly) (Ainsworth et al., 2000).   
 
For example, the MET hour score for one month for a patient who ran for one 
hour, five days a week was calculated as follows: 
Hours per week  = number of hours per day × number of days per week 
   = 1 hour per day × 5 days per week 
   = 5 hours per week 
 
Hours per month = number of hours per week × 4.3 weeks per month 
   = 5 hours per week × 4.3 weeks per month 
   = 21.5 hours per month  
 
The metabolic equivalent of running is 8 METS, therefore: 
Met hours per month = hours per month × metabolic equivalent 
   = 21.5 hours per month × 8 METS 
   = 172 MET hours per month 
 
A total MET hour score for one month was calculated by summing the METS 
obtained for each activity.  Determining the total MET hour score for one month 
allowed for the evaluation of the contributions of various types of physical 
activity to energy expenditure. 
 
  
 
2.2.3 Statistical Analysis 
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Data are shown as mean ± standard deviation unless otherwise stated.  
Spearman’s correlations were done to determine the relationships between CD4 
cell count and length of time on ARV medication, CD4 cell count and total 
habitual physical activity, CD4 cell count and degree of functional dependency as 
well as the relationship between total habitual physical activity and length of time 
on ARV medication and total habitual physical activity and degree of functional 
dependency. 
 
Mann-Whitney tests were done to determine differences between the CD4 cell 
count of the male and female patients, the CD4 cell count of patients taking and 
not taking ARV medication and the CD4 cell count of patients considering 
themselves either functionally independent or dependent.  Mann-Whitney tests 
were also used to determine differences between the total habitual physical 
activity levels of the male and female patients, and the total habitual physical 
activity levels of patients taking and not taking ARV medication. 
 
Kruskal-Wallis tests were done to determine differences in CD4 cell count and 
differences in total habitual physical activity between patients experiencing no 
side effects from ARV medication use, patients experiencing one side effect, two 
side effects, three side effects and four or more side effects from ARV medication 
use. 
 
For all statistical analysis, significance was set at P < 0.05. 
 
2.3 Physiological Evaluation 
2.3.1 Participants 
A convenience sample of ten HIV positive black female outpatients were 
recruited from the antiretroviral roll out site based at Helen Joseph Hospital to 
participate in the study.  The patients were all taking ARV medication and were 
aged between 20 and 45 years of age (34.0 ± 5.7; mean ± SD).  The experimental 
protocol was approved by the University of the Witwatersrand Committee for 
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Research on Human Subjects (Protocol Number M051127; Appendix A).  All 
subjects gave written consent for participation.  Before commencement of the 
exercise testing sessions, the patients were questioned on their health to ensure 
they had not suffered from any infections in the past three months and were not 
taking any chronic medication, other than ARV medication, nor suffered from any 
orthopedic or joint problems.    
 
Ten HIV negative age-matched black females were recruited to participate as 
control subjects. The control subjects were between the ages of 20 years and 45 
years of age (32.5 ± 5.4; mean ± SD).  Subjects were medically screened to ensure 
they were healthy and able to exercise.  The experimental protocol was approved 
by the University of the Witwatersrand Committee for Research on Human 
Subjects (Amended Protocol M051127; Appendix A).  All subjects gave written 
consent for participation.  HIV negative status was confirmed with an ELISA 
diagnostic HIV test, with analysis performed by the National Health Laboratory 
Service based at Johannesburg General Hospital, Parktown, Johannesburg.  Pre- 
and post-HIV test counseling was provided to each control subject by a qualified 
HIV counselor and registered nurse.    All the control subjects followed the same 
study procedures as the HIV positive patients. 
 
2.3.2 Blood Analysis 
Patients were required to have a blood test one week before participating in the 
exercise tests.   The blood sample was analysed by the National Health 
Laboratory Service at Johannesburg General Hospital, Parktown, Johannesburg 
for current CD4 cell count, full blood count and glycated hemoglobin (HbA1c).  
Glycated hemoglobin was assessed to provide an indication of glucose levels over 
a three month period.  In addition, a finger prick lactate test was performed using 
an Accusport Lactate Machine (Model 1488767, Boehringer Mannheim GmbH, 
Manneheim, Germany) to determine the random resting lactate levels of each 
patient.  Lactate was used as an indirect assessment of detecting lactic acidosis.   
Blood samples were obtained in the morning, in a non-fasted state. 
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2.3.3 Activity Monitor 
Each patient received an Actical® Version 2.0 activity monitor (Mini Mitter 
Company Inc, Oregon) to wear for one full week (five week days and two 
weekend days) in order to objectively measure physical activity levels over that 
specific period of time.  The Actical®, an omnidirectional accelerometer, is a 
small match-box sized device (28×27×10 mm) and weighs 17 g.  It was worn 
around the waist, underneath the patients clothing, slightly medial to the left 
anterior superior iliac spine and provided a quantifiable measure of physical 
activity without hindering movement.  The Actical® was worn at all times, except 
when the patient bathed or swam.  Patients were educated on how to reattach the 
actical after it had been removed for bathing purposes.  Physical activity counts 
were expressed as a percentage of the maximum count measured for the Actical® 
over the seven days. 
 
2.3.4 Anthropometry 
The anthropometric assessment followed the protocol as stated by the MOGAP 
procedure (Norton et al., 1996).  The patients’ height was measured to the closest 
millimeter using a Seca wall-mounted stadiometer (Seca, Hamburg, Germany).  
Body mass to the closest 0,05g was measured in minimal clothing and without 
shoes using a Mettler TE Industrial Precision digital scale (Mettler Instrumente 
AG, GreiFensee, Switzerland).  Body mass index was calculated as body mass 
(kg) divided by height2 (m2).  The circumference of the waist was measured at the 
level of the narrowest point between the lowest costal border and the iliac crest.  
Hip circumference was taken at the level of the greatest posterior protuberance of 
the buttocks approximately corresponding anteriorly to the level of the symphysis 
pubis.  Both circumferences were measured using a standard non-distendable 
measuring tape.  Waist:hip ratio (WHR) was calculated as waist circumference 
(cm) divided by hip circumference (cm).  
 
2.3.5 Aerobic capacity 
The YMCA Submaximal Bicycle Ergometer Protocol (Golding et al., 1989) was 
used to determine the physical work capacity of each patient.  The bicycle used 
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was a Monark friction-braked, cadence dependent cycle ergometer.  The subject 
was seated on the cycle ergometer so that the knee angle formed was 
approximately 120 degrees with the pedal at the dead bottom centre in the 6 
o’clock position.  A gentle warm up of five minutes was performed to allow the 
patients to become familiar with the testing equipment as well as for the bike to 
be set up to accommodate each subject correctly.  Pedal cadence was set at 
between 50 and 60 revolutions per minute, with each subsequent workload lasting 
four minutes.  The first workload was set at 25 watts (150kg.m.min-1).  This 
workload was performed for four minutes until a steady state heart rate was 
achieved.  Subsequent workloads were then set according to Table 2.1. 
 
Table 2.1 Subsequent workloads of the YMCA Submaximal Protocol 
Heart Rate a < 80 bpm 80-89 bpm 90-100 bpm > 100bpm 
Workload 2 750kg.m.min-1 * 
125 watts # 
2.5kg $ 
600kg.m.min-1 
100 watts 
2.0kg 
450kg.m.min-1 
75 watts 
1.5kg 
300kg.m.min-1 
50 watts 
1.0kg 
Workload 3 900kg.m.min-1 
150 watts 
3.0kg 
750kg.m.min-1 
125 watts 
2.5kg 
600kg.m.min-1 
100 watts 
2.0kg 
450kg.m.min-1 
75 watts 
1.5kg 
Workload 4 1050kg.m.min-1 
175 watts 
3.5kg 
900kg.m.min-1 
150 watts 
3.0kg 
750kg.m.min-1 
125 watts 
2.5kg 
600kg.m.min-1 
100 watts 
2.0kg 
a Subsequent workloads are chosen dependent on the heart rate response to the first workload of 
25 watts (or 150kg.m.min-1) i.e., if the patients heart rate was less than 80 beats per minute, a 
second workload of 125 watts (or 750kg.m.min-1), using a weight of 3.0kg as resistance. 
*Represents the workload in kilogram meters per minute.  On a Monark cycle ergometer, the 
flywheel travels 6 meters per pedal revolution.  Resistance is set with a weighted pendulum, and 
the workload is calculated as follows: 
Workload = resistance in kg × revolutions per minute × revolutions per minute 
 # represents the power output of the workload in watts (1 watt = 6kg.m.min-1) 
 $ represents the weight of the weighted pendulum (i.e. resistance) in kg 
Heart rate was measured using a Polar S610 Heart Rate Monitor (Polar Electro 
Oy, Kempele, Finland).  The test was terminated once the patient could not 
maintain the pedal cadence and could not continue with the test.  Predicted 
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maximal oxygen uptake was then calculated using an extrapolation graph by 
plotting power output (in kilogram meters per minute or kg.m.min-1) and the 
corresponding heart rate achieved for each workload.  From the graph, the 
workloads at a heart rate of 150bpm and 170bpm were also calculated. 
 
Patients were asked to rate their perceived exercise exertion on a scale of one (1) 
to ten (10) using the OMNI-Cycle Scale of perceived exertion for adults 
(Robertson et al., 2004).  This rating of perceived exertion was used as a marker 
for level of difficulty and provided a subjective indication of the amount of 
tiredness experienced by the subject.   
 
2.3.6 Muscle Strength and Endurance 
Muscle strength of the quadriceps and hamstring muscles of the dominant leg of 
each patient was measured using a Cybex II isokinetic dynamometer (Cybex, 
Ronkonkoma, New York, USA).  The dominant leg was defined as the one 
preferred for daily activities, for example, kicking a soccer ball.  The cycle 
ergometer test was used as the warm up before the isokinetic testing.  Patients 
were taken through a stretching routine of the calves, hamstrings and quadriceps.  
A brief warm up was allowed on the Cybex to allow each patient to familiarize 
herself with the equipment.  The quadriceps and hamstrings were isolated by 
stabilizing the waist and thigh of the non-dominant leg.  Gravity correction was 
done by allowing compensation for gravity assisted knee flexion.  Range of 
motion for the test was between zero and 90 degrees.  Patients were given a warm 
up by performing one repetition each at 25%, 50% and 75% of maximum knee 
extension and flexion as well as two maximal repetitions which were done at a 
speed of 60 degrees per second.  A rest period of 90 seconds was allowed before 
commencement of the strength test protocol which consisted of four maximal 
repetitions at a speed of 60 degrees per second.   
 
Hand grip strength of the dominant hand was measured using a Jamar Hand 
dynamometer (Sammons Preston Inc, Bolingbrook, Illinois).  The dominant hand 
was defined as the one preferred for daily activities such as writing.  Grip strength 
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was measured in a standing position with the shoulder adducted and neutrally 
rotated and the elbow in full extension.  Results were recorded in kilograms.  The 
patients performed three maximal attempts and the highest value was recorded. 
 
2.3.7 Statistical Analysis 
Data are shown as mean ± standard deviation unless otherwise stated.  Unpaired 
student t-tests were done to determine for significant differences between the 
anthropometric and physiological variables of the HIV positive patients and the 
HIV negative controls.  The anthropometric variables included age, height, mass, 
body mass index (BMI), and waist hip ratio (WHR), and the physiological 
variables included relative maximal oxygen consumption, lower limb muscle 
strength (peak torque of hamstrings and quadriceps), handgrip strength and 
physical activity count. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 – Lifestyle and Physical Activity Questionnaire 
 
3.1 Introduction 
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This chapter presents the results of the Lifestyle and Physical Activity 
Questionnaire, including demographic information and HIV history of the 
patients, their use of antiretroviral (ARV) medication, details of their habitual 
physical activity levels as well as their functional independence. 
 
3.2 Demographic Information 
A total of 186 black outpatients from an ARV roll out site in Johannesburg 
completed the questionnaire.  Of this group 25% were male and 75% were 
female.  The mean ± SD age of the patients (both males and females) was 36 ± 8 
years.  The mean ± SD age of the male patients was 36 ± 7 years and of the 
female patients was 35 ± 8 years.  A breakdown of the socioeconomic status of 
the patients including employment status, income per month, educational 
qualification and area of residence is shown in Table 3.1. 
 
Table 3.1: Socioeconomic characteristics of the patients (both genders) 
Socioeconomic Variable n % 
Unemployed 101 54 Employment status 
Employed 85 46 
No income 101 54 
Less than R1000 30 16 
Between R1000-R5000 51 27 
Income per month 
Between R5000-R10000 4 2 
No education 9 5 
Lower than Grade 7 25 13 
Between Grade 7 – Grade 11 83 45 
Grade 12 64 34 
Highest educational 
qualification 
Post matric certificate 5 3 
Homeless 1 1 
Traditional village 22 12 
Area of residence 
Informal township 21 11 
Formal township 93 50 
Low income housing 3 2 
Middle class suburb 20 11 
 
Upper class suburb 26 14 
3.3 HIV History 
The majority of the patients (49%) had been diagnosed with HIV for one year or 
less before completing the questionnaire.  Of the remaining patients, 17% had 
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been diagnosed between one and two years before completing the questionnaire, 
10% had been diagnosed with HIV for more that two years, 7% for more than 
three years, 4% for more the four years, and 12% for more that five years.  The 
remaining 1% of the patients did not know when they had been diagnosed with 
HIV.  At the time of the study, the CD4 cell count range of the patients was 3 to 
1031cells/mm3, with a median CD4 cell count of 195 cells/mm3.  The male 
patients had a significantly lower median CD4 cell count (median = 135 
cells/mm3; range = 9 to 475 cells/mm3) than the female patients (median = 203 
cells/mm3; range = 3 to 1031 cells/mm3) (P = 0.024, Mann-Whitney test).   
 
3.4 Use of Antiretroviral (ARV) Medication 
A total of 121 (65%) patients were on ARV medication.  The majority of patients 
were on first line treatment, consisting of Lamivudine and Stavudine (both 
nucleoside reverse transcriptase inhibitors) and either Efavirenz or Nevirapine 
(both non-nucleoside reverse transcriptase inhibitors), depending on whether the 
patient was on reliable contraception.  Of the 121 patients who were taking ARV, 
30 (25%) were male and 91 (75%) were female.  No significant association was 
found between gender and ARV use (P = 0.86, Fishers Exact test).  The length of 
time these patients had been receiving ARVs ranged from two weeks to 32 
months (median = 7 months). As seen in Figure 3.2, there was a positive 
correlation between CD4 cell count and length of time on ARV medication 
(Spearman’s correlation, P < 0.0001, r = 0.45).   
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Figure 3.1: The correlation between CD4 cell count and length of time on ARV 
medication (Spearman’s correlation, P < 0.0001; r = 0.45) 
 
The most common side effects experienced by patients using ARV medication are 
shown in Figure 3.3. There was no significant difference in the CD4 cell counts of 
the patients who had not experienced side effects from ARV medication use and 
patients who experienced one, two, three and four side effects from medication 
use (P = 0.79, Kruskal-Wallis test).   
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Figure 3.2: The percentage of patients who experienced side effects from ARV use (n = 
121). 
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Of the patients using ARV medication, 84% believed that use of ARV medication 
increased their habitual physical activity levels, 3% believed that the use of the 
medication decreased their habitual physical activity levels, and 14% felt no 
change in their habitual physical activity levels. There was, however, a significant 
association between use of ARV medication and patients reporting sleep 
disturbances (P = 0.019, Fishers Exact test). 
 
3.5 Habitual Physical Activity Information 
Table 3.2 shows the contributions of the various types of physical activities 
[inactivity (sleep, relaxation), occupational, household and recreational] to total 
habitual physical activity levels in the male and female patients.  The scores 
presented in the table are in MET hours per month.  There was no significant 
difference in any of the contributions to or in total habitual physical activity 
levels between the male and the female patients (P = 0.19, Mann-Whitney test). 
 
Table 3.2: Contribution of the various types of physical activity levels (MET 
hours*/month) to the total monthly habitual physical activity levels in the male 
and female patients 
Activity Males Females 
Inactivity 
(sleep, relaxation) 
342 + 99  
(n = 47) 
349 + 103  
(n = 139) 
Occupational 688 + 265  
(n = 21) 
706 + 379 
(n = 64) 
Household 76 + 55  
(n = 34) 
159 + 114  
(n = 132) 
Recreational 114 + 139  
(n = 26) 
99 + 104  
(n = 62) 
Total 770 + 420  
(n = 47) 
869 + 443  
(n = 139) 
Data is shown as mean ± SD 
n = number of patients who participated in that specific activity 
* The above scores represent multiples of one MET.  One MET is defined as the energy 
expenditure for sitting quietly, which for the average adult is approximately 3.5ml of oxygen per 
kg body body mass per minute (Ainsworth et al., 2000). 
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The relationship between CD4 cell count (cells/mm3) and total habitual physical 
activity level is shown in Figure 3.4.  There was a positive correlation between 
CD4 cell count and total habitual physical activity (Spearman’s correlation, P = 
0.0067, r = 0.20; Figure 3.4). There was no significant difference in the CD4 cell 
counts when the total habitual physical activity levels were separated into low (0 
to 500 MET hours per month), low to medium (500 to 1000 MET hours per 
month), medium (1000 to 1500 MET hours per month) and high categories 
(greater than 1500 MET hours per month) (P = 0.095; Kruskal-Wallis test).   
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Figure 3.3: The correlation between CD4 cell count (cells/mm3) and total habitual 
physical activity levels (MET hours*/month) for the male and female patients (n = 186) 
(Spearman’s correlation, P = 0.0067, r = 0.20) 
* The scores in the above figure represent multiples of one MET.  One MET is defined as the 
energy expenditure for sitting quietly, which for the average adult is approximately 3.5ml of 
oxygen per kg body body mass per minute (Ainsworth et al., 2000). 
 
There was no significant correlation between total habitual physical activity level 
and length of time on ARV medication (Spearman’s correlation, P = 0.83,               
r = -0.020).  There were no significant differences in the total habitual physical 
activity levels of patients who had not experienced side effects from ARV 
medication use and patients who had experienced one side effect, two side effects, 
three side effects and four side effects (P = 0.66, Kruskal-Wallis test).   
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3.6 Functional Dependency 
Of the total 186 patients, 12 patients (7%) reported difficulty independently 
performing one or more of the tasks of daily living listed in the questionnaire, and 
were as such classified as being functionally dependent on others for help. 
 
Patients who considered themselves functionally independent i.e., not needing 
help, had a significantly higher CD4 cell count than patients who did not think 
they were functionally independent (P = 0.0031, Mann-Whitney test; Figure 3.5).  
There was a significant correlation between CD4 cell count and degree of 
subjective functional dependency (Spearman’s correlation, P = 0.0024, r = -0.22). 
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Figure 3.4: A box and whisker representation of the CD4 cell counts (cells/mm3) of the 
patients who were functionally independent (n = 174) and functionally dependent on 
others for help (n = 12).  The patients who were functionally dependent on others for help 
had a significantly lower CD4 cell count (* P = 0.003) 
  
There was no significant difference between the total habitual physical activity 
levels of the patients who were functionally independent and dependent on others 
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for help (P = 0.12, Mann-Whitney test) and no significant correlation between 
total habitual physical activity levels and subjective functional dependency 
(Spearman’s correlation, P = 0.12, r = -0.11). 
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Chapter 4 – Physiological Evaluation 
 
4.1 Introduction 
This chapter presents the findings of the physiological evaluation of a sample of 
HIV positive black female patients and HIV negative black female age-matched 
controls.  The subjects’ physical characteristics, blood analysis, aerobic capacity, 
muscle strength and habitual physical activity counts are presented. 
 
4.2 Physical Characteristics 
Ten HIV positive black females (aged 34 ± 6 years) recruited from an ARV roll 
out site in Johannesburg participated in this study.  The patients were receiving 
first line treatment consisting of a combination of Lamivudine, Stavudine and 
Efavirenz, and had been taking these medications for a time period ranging from 
two months to 84 months (median = 7 months).  Ten black age-matched HIV 
negative females (aged 32 ± 6 years) acted as their controls.  Table 4.1 describes 
the physical characteristics of the HIV positive patients and HIV negative control 
subjects. 
 
Table 4.1: Physical characteristics of the HIV positive patients and HIV negative 
controls 
    HIV positive patients  HIV negative controls 
 
Height (m)         1.59 ± 0.07         1.57 ± 0.05 
Mass (kg)         68.5 ± 13.0         73.7 ± 15.7 
BMI * (kg/m2)         26.9 ± 3.3         29.7 ± 5.1 
WHR #          0.81 ± 0.08         0.75 ± 0.11   
Data are presented as mean ± SD 
* BMI = Body Mass Index: calculated as mass (kg)/height2 (m) 
# WHR = Waist Hip Ratio: calculated as waist circumference (cm)/hip circumference (cm) 
There was no significant difference in the physical characteristics between the HIV positive 
patients and HIV negative controls (Unpaired t-test, P > 0.05) 
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4.3 Blood Analysis 
The blood analysis results for the HIV positive patients and HIV negative controls 
are presented in Table 4.2.   
 
Table 4.2: Blood test results of the HIV positive patients and HIV negative 
controls 
   HIV positive patients  HIV negative controls  Reference Ranges 
 
Hemoglobin (g/dl)  13.6 ± 1.3   13.7 ± 0.9   14.3 – 18..3 
Hematocrit (%)  40 ± 3   41 ± 2   43.0 – 55.0  
Resting Lactate (mmol/l) 2.2 ± 0.9   1.9 ± 0.4   2.0 -5.0 
Glycated hemoglobin (%) 5.4 ± 0.3   5.9 ± 0.3#   < 7% 
CD4 cell count (cells/mm3)  246 ± 124   819 ± 194 *  500 - 2010 
Data are presented as mean ± SD 
# P = 0.0011 
* P < 0.0001 
 
The HIV negative control subjects had a significantly higher percentage glycated 
hemoglobin (HbA1c) than their HIV positive counterparts (P = 0.0011, t = 3.87, 
df = 18, Unpaired t-test).  The HIV positive patients had a significantly lower 
CD4 cell count than the HIV negative control subjects (P < 0.0001, t = 7.86, df = 
18, Unpaired t-test). 
 
4.4 Aerobic Capacity 
The predicted relative maximal oxygen uptake (VO2max) of the HIV positive 
patients was not significantly different to that of the HIV negative controls (P = 
0.26, t = 1.16, df = 18, Unpaired t-test; Figure 4.1). 
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Figure 4.1: The predicted relative maximal oxygen uptakes (VO2max, ml.kg-1.min-1) of the 
HIV positive patients and HIV negative controls (mean + SD). 
 
4.5 Muscle Strength 
The peak torque (Nm) of the hamstring and quadriceps muscles of the HIV 
positive patients and HIV negative controls are shown in Figures 4.2 and 4.3 
respectively.  No significant difference was found between the mean  hamstring 
muscle peak torque (Nm) of the HIV positive patients (70.38 Nm)  and the HIV 
negative controls (76.80 Nm) (P = 0.22, t = 1.27, df = 17, Unpaired t-test; Figure 
4.2). 
 
No significant difference was found between the mean quadricep muscle peak 
torque of the HIV positive patients (118.46 Nm) and the HIV negative controls 
(123.0 Nm) (P = 0.87, t = 0.16, df = 18, Unpaired t-test; Figure 4.3). 
 
The mean handgrip strength of the HIV positive patients (35.69 kg) was not 
significantly different to the mean handgrip strength of the HIV negative controls 
(34.45 kg) (P = 0.52, t = 0.66, df = 18, Unpaired t-test). 
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Figure 4.2: The hamstring muscle peak torque (Nm) of the HIV positive patients and HIV 
negative controls (mean + SD). 
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Figure 4.3: The quadricep muscle peak torque (Nm) of the HIV positive patients and HIV 
negative controls (mean ± SD).   
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4.6 Physical Activity Count 
The seven day physical activity counts, expressed as a percentage of the 
maximum count for each individual, are shown in Figure 4.4.  There was no 
significant difference between the physical activity counts of the HIV positive 
patients and HIV negative controls (P = 0.55, t = 0.61, df = 18, Unpaired T-test).  
The physical activity count includes the hours when the HIV positive patients and 
HIV negative controls were awake and asleep. 
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Figure 4.4: The seven day physical activity counts (% of maximum count for that 
individual) of the HIV positive patients and HIV negative controls (mean + SD).  There 
was no significant difference in the activity counts between the HIV positive patients and 
HIV negative controls (P = 0.55). 
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Chapter 5 – Discussion and Conclusions 
 
5.1 Discussion 
The purpose of this study was to determine the association between HIV 
infection, and use of antiretroviral (ARV) medication on habitual physical activity 
(PA) levels, functional independence as well as measured exercise capacity and 
measured activity counts, in a sample of HIV positive South African adults.  This 
chapter discusses and contextualizes the results of the Lifestyle and Physical 
Activity Questionnaire as well as the results of the Physiological Evaluation. 
 
A convenience sample of black HIV positive patients who frequented an 
antiretroviral (ARV) roll out site within the Johannesburg area was recruited to 
participate in this study.  A total of 186 HIV positive male and female patients 
completed the questionnaire, and a total of 10 HIV positive females participated 
in the physiological evaluation.  The majority of the patients fell into a lower 
socio-economic bracket and were unemployed.  Those that were employed 
reported a monthly income of between R1000 and R5000.  The majority of 
patients had obtained a matric certificate and resided within a formal township. 
 
The study assessed firstly, using a Lifestyle and Physical Activity Questionnaire, 
the relationship between CD4 cell count (a marker of immune status), amount of 
habitual physical activity (PA) and degree of subjective independence in a group 
of black male and female HIV positive out-patients (n = 186).  These patients 
were recruited from an antiretroviral (ARV) roll out site within the Johannesburg 
area and were either not taking ARV medication (n = 65), or had been on the 
ARV medication (n = 121) for a time period ranging from two weeks to 32 
months (median time = 7 months).  As far as I am aware, this study is the first to 
assess this relationship in a SA population and forms a valuable foundation for 
further investigation, particularly the relationship between long term ARV 
medication use (greater than three years) and physical well-being in HIV positive 
individuals.   
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Analysis of the questionnaire showed that there was a positive and significant 
correlation between CD4 cell count and length of time on ARV medication, 
implying that the long term use of ARV medication, albeit only for a median time 
of seven months in these patients, improves CD4 cell count and helps maintain 
immune status.  The positive and significant correlation between CD4 cell count 
and total habitual physical activity (PA) levels suggests an association between 
CD4 cell count and total habitual habitual PA.  Furthermore, patients who 
considered themselves to be functionally independent, and not requiring help 
from others in performing tasks of daily living, had a significantly higher CD4 
cell count than those patients who needed help to perform these tasks.  Therefore, 
my results show that the use of ARV medication, albeit only for a median time of 
seven months in my patients, is associated with a higher CD4 cell count (an 
indicator of slower HIV disease progression) which translates into an increased 
total habitual PA level and greater sense of functional independence. 
 
ARV therapy, as with any other drug therapy, is associated with acute and chronic 
drug administration side effects which could decrease physical well being and 
impact negatively on functional independence.  Despite the literature reporting the 
possible physical activity limiting side effects associated with the use of ARV 
medication, and many of my patients experiencing one or more of these side 
effects within the past year or since commencing ARV administration, 85% of 
these patients still believed that the use of ARV medication increased their total 
habitual PA levels.  Furthermore, the total habitual PA levels of the patients who 
had experienced one or more side effects from ARV administration and those 
patients who had not experienced any side effects, were not statistically different.  
Therefore, these results highlight the benefit of ARV medication, despite side 
effects, in improving immune status, increasing PA levels and maintaining 
functional independence in HIV positive patients.  The patients in my study had 
only been using ARV medication for a relatively short time (median time of seven 
months; range: two weeks to 32 months), and therefore more research would need 
to be done to determine whether the often more serious side effects associated 
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with longer administration of ARV medication would begin to have a negative 
impact on physical well-being. 
 
In the second part of my study, I assessed the full blood counts, aerobic capacity, 
lower limb and handgrip strength, and seven day physical activity (PA) counts of 
ten HIV positive black females recruited from the same Johannesburg ARV roll 
out site.  All these patients were on first line ARV treatment consisting of 
Stavudine, Lamivudine and Efavirenz and had been taking ARV medication for a 
time period ranging from two months to 84 months (median time = 7 months).  
Ten HIV negative age-matched black females acted as their controls.  My results 
show no significant differences in hemoglobin, hematocrit, and resting blood 
lactate levels between the two groups.  The HbA1c (glycated hemoglobin) level, 
an indicator of plasma glucose concentration over a time period of approximately 
three months,  was significantly lower in the HIV positive patients compared to 
the HIV negative controls.  However, both groups’ HbA1c results were within the 
normal range.  The body mass index (BMI), although high in both groups, and 
waist hip ratio (WHR) were not statistically different between the two groups.  I 
have also shown that the aerobic capacity (predicted VO2 max) and lower limb 
and hand muscle strength of the two groups were not significantly different.  
Although a small representation of the HIV positive population, my results show 
that the patients who are infected with HIV and have been taking ARV 
medication for a median time of 7 months are as aerobically and muscularly 
strong as their HIV negative counterparts.  In addition, the seven day PA counts 
(actigraphy) of the HIV positive patients were not statistically different to those of 
the HIV negative controls, suggesting that they were as physically active as the 
HIV negative controls.  My results could suggest that either the HI virus does not 
negatively impact on physical well being until much later in the progression of the 
disease, or that the use of ARV medication, although only short term in this 
group, has slowed down the disease progression, and maintained physical well 
being.  If the latter is true, the documented side effects of ARV medication, as 
reported in the literature and in the questionnaire, have not negatively affected 
physical well being in these HIV positive patients.  However, as suggested 
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previously, more research to determine if side effects from longer ARV use will 
negatively impact on physical well-being is needed.  
 
The results obtained from my two studies are not representative of the South 
African HIV positive population in its entirety.  As stated by the constitution, HIV 
positive patients have a right not to disclose their HIV status, and therefore access 
to an HIV positive population was limited to a sample from a major public HIV 
clinic within the Johannesburg area who fell into a lower socio-economic bracket.  
Therefore, my study did not include HIV positive patients from the private health 
sector nor did it include patients from different racial, cultural and socio-
economic backgrounds other than this specific black population group.   
 
Although the sample size of the questionnaire based study was relatively small, 
the use of a questionnaire was still the easiest and least expensive and time 
consuming technique to assess the habitual physical activity levels in this 
population.  The Lifestyle and Physical Activity Questionnaire was developed to 
compare the habitual physical activity behaviours between different population 
groups, and not to assess the habitual physical activity levels in an HIV positive 
population only.  Since the questionnaire was used to obtain exploratory data, it 
was not validated specifically in an HIV positive population and as such is a 
limitation of the study.  Validation of a questionnaire required comparison of the 
results to that of a control group i.e., HIV negative participants, which was 
beyond the scope of this study, both ethically and logistically. 
 
Another limitation of this method of assessment is the subjective nature of a self-
reported questionnaire.  Questionnaire responses are dependent on a patient’s 
bias, his/her inaccurate perception of the frequency and intensity of physical 
activity performed as well as his/her ability to recall the exact volume of physical 
activity performed.  Also, patients are influenced by the perceived desirability of 
their responses i.e., what would be considered a good answer?  As a result, most 
patients will overestimate the amount of physical activity performed.  Another 
limitation is that every day tasks which contribute to habitual physical activity, 
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such as walking and domestic activities, are easily overlooked as many patients 
perceive physical activity as being structured exercise, rather than any type of 
bodily movement resulting from skeletal muscle contraction.  Therefore, physical 
questionnaires are valuable in obtaining data from large population groups but are 
limited in their accuracy. 
 
For comparative purposes, physical activity information gained from the 
questionnaire used in this study was converted to an estimate of caloric 
expenditure or multiples of resting metabolic rate (METS).  One MET is defined 
as the energy expended during quiet sitting and is the ratio of work metabolic rate 
to a standard resting metabolic rate of 1.0 (4.184kJ per kg per hr) (Ainsworth et 
al., 2000).  Although METS (multiples of average resting metabolic rate) will be 
the same across all populations, conversion into actual energy expenditure for 
comparison purposes between HIV positive and HIV negative populations cannot 
be accomplished accurately because of the higher resting energy expenditure (EE) 
and hypermetabolic nature of HIV positive patients (Macallan et al., 1995; 
Suttman et al., 1993).   More research into this field is required and as such, this 
study did not compare the total habitual physical activity levels (MET hours per 
month) between HIV positive and HIV negative individuals.  Furthermore, 
because potential HIV negative controls subjects would have to be asked to 
disclose their HIV status, or many costly HIV tests and counseling sessions would 
have to be performed to determine their status, I was ethically and financially 
unable to administer the questionnaire to HIV negative control subjects.  As such, 
the questionnaire was only completed by HIV positive patients and did not 
compare the habitual physical activity levels between HIV positive patients and 
HIV negative control subjects. 
 
A physiological evaluation was therefore completed which investigated the 
aerobic capacity, lower limb muscle strength, hand grip strength and physical 
activity counts (actigraphy) in a group of black HIV positive females and a group 
of age-matched HIV negative control subjects.  A limitation of the physiological 
evaluation was the small sample size.  HIV positive patients who were 
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approached were reluctant to participate in the study for various reasons.  It was 
also difficult to obtain HIV negative control subjects, firstly, because some 
subjects were afraid and therefore unwilling to take an HIV test, and secondly, 
due to the difficulty of finding HIV negative black females who were age-
matched to the HIV positive patients.  Post hoc analysis revealed that 
approximately 30 more subjects would be required to see significant differences 
in aerobic capacity, muscle strength and physical activity counts between the two 
groups, and not necessarily greater in the HIV negative controls.  Although the 
HIV positive patients and HIV negative controls did not complete the Lifestyle 
and Physical Activity Questionnnaire, a limitation in the study, I was able to 
objectively measure their physical activity counts using activity monitors 
(actigraphy), a novel technique which is as reliable, if not more accurate, than 
questionnaire based activity studies.  Indeed, this study is the first to use activity 
monitors to objectively measure physical activity counts in HIV positive patients. 
Another limitation of this study was the use of a submaximal bicycle ergometer 
test.  The majority of patients had not been on any form of bicycle before 
participation in this study and therefore struggled to maintain peddle cadence 
during the test.  However, this was true for both groups and the use of this test 
was not biased toward a specific group.  A better alternative for future studies 
would be the six minute walk test (American Thoracic Society, 2002; Solway et 
al., 2001) to assess aerobic fitness of individuals not comfortable using a 
stationary cycle ergometer.  The six minute walk test is also a better reflection of 
the functional exercise level required for daily physical activities. 
 
Despite these limitations, my study has still made significant inroads into the 
assessment of total habitual physical activity habits and exercise capacity of HIV 
positive individuals.  ARV medication is used to improve the immune status of 
HIV infected individuals by increasing and stabilizing CD4 cell count and 
decreasing HIV viral load to undetectable levels (Grimwood, 2004; Department 
of Health, 2003).  I have shown that the use of ARV medication, despite side 
effects, results in a higher CD4 cell count, and a higher habitual physical activity 
level and greater functional independence. Furthermore, HIV positive women 
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who are taking ARV medication have an aerobic capacity, muscle strength and 
physical activity count which is not statistically different to their HIV negative 
peers. 
 
South Africa is said to have more people infected with HIV than any other 
country (WHO, 2006), a statistic which places a great financial and social burden 
on the infrastructure of the country.  HIV infection is associated with various 
physiological symptoms and manifestations.  Various metabolic syndromes are 
observed as the disease progresses (Stringer et al., 2001), which can severely 
decrease physical activity levels and functional independence.  A major 
component of HIV infection is severe body mass loss and body wasting 
(Hellerstein et al., 1990; Chlebowski et al., 1989; Kottler et al., 1985) and the 
morbidity of the wasting process plays a major role in the decreased quality of life 
of these patients (Hellerstein et al., 1990).  The subsequent decreased muscle 
mass causes a decrease in the overall functional status of individuals infected with 
HIV, including decreased exercise performance, aerobic capacity and lower body 
muscle strength (Grinspoon et al., 1996).  Weakness and fatigue are among the 
most troubling and debilitating symptoms reported by HIV positive patients 
(Hellerstein et al., 1990), and can certainly decrease functional independence and 
decrease quality of life.  However, in my study, the female HIV positive patients 
showed no signs of severe body mass loss or body wasting and their aerobic 
capacity, muscle strength and physical activity counts were not significantly 
different to their age-matched counterparts.  Perhaps the HI virus does not 
negatively impact on physical well-being until much later in the progression of 
the disease, or the use of ARV medication, albeit only short term in this group, 
and not without side effects, has improved immune status and physical well-
being. 
 
In this study, 65% of the patients who completed the questionnaire, and all the 
patients who participated in the physiological evaluation, were taking ARV 
medication.  Although ARV medication is used specifically to increase CD4 cell 
count and to decrease the HIV viral load in patients infected with the disease, the 
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South African Department of Health has set criteria which have to be met before 
ARV treatment can commence (Department of Health, 2003).  Only patients who 
have a CD4 cell count of less than 200 cells/mm3 or lower, or are symptomatic 
qualify for ARV treatment.  Once ARV treatment has been started, patients will 
take the medication for life to prevent drug resistance, despite an increase in their 
CD4 cell count, suppression of viral load and increased health and well being 
(Griffen, 2003).  The results of my questionnaire show that use of ARV 
medication is associated with enhanced immunity which has a positive impact on 
total physical activity levels and functional independence.  Bopp et al. (2004) 
showed that an inverse relationship exists between mean physical activity levels 
and viral load, suggesting increased activity levels has beneficial effects on viral 
load of HIV infected individuals.  Furthermore, the female HIV positive patients 
who were taking ARV medication had an aerobic capacity, lower limb muscle 
strength, hand grip strength and seven day physical activity count which were not 
statistically different to their age-matched HIV negative counterparts. 
 
The majority of patients in this study were on first line treatment, consisting of 
Lamivudine and Stavudine (nucleoside reverse transcriptase inhibitors or NRTI) 
and either Efavirenz or Nevirapine (non-nucleoside reverse transcriptase 
inhibitors or NNRTI).  The side effects associated with the use of ARV 
medication have been well documented in the literature.  ARV therapy has been 
associated with troubling symptoms such as fatigue, dyspnoea (shortness of 
breath) and metabolic and body composition abnormalities (Hellerstein, 2001; 
Jones et al., 2001; Stringer et al., 2001) as well as gastrointestinal pain, nausea, 
vomiting, diarrhea, loss of appetite, constipation and heartburn (Department of 
Health, 2004).   
 
Nucleoside reverse transcriptase inhibitors (NRTI) have been associated with side 
effects such as diarrhea, pancreatitis, and lactic acidosis.  Short term side effects 
associated with NNRTIs include dizziness, insomnia, abnormal dreams and 
hallucinations (with Efavirenz) and nausea and vomiting (with Nevirapine).  
These side effects are considered short term and resolve themselves after a few 
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weeks on ARV therapy.  ARV therapy, especially combination therapy using 
NRTIs, has also been shown to disrupt normal mitochondrial functioning (Cade et 
al., 2004), which negatively impacts on ATP production via oxidative 
phosphorylation.  This limitation in oxygen delivery to working muscles has been 
identified as a mediator of diminished aerobic capacity, and can increase exercise 
intolerance.  Distal symmetric polyneuropathy, another side effect of ARV 
medication, is characterized by a loss of primary afferent fibers, resulting in distal 
axonal degeneration and symptoms of pain and paraesthesia in the distal 
extremities and can cause gait difficulties (Verma et al., 2005).  The symptoms of 
distal axonal degeneration and decreased muscle oxygen delivery, as well as the 
other side effects of ARV medication, can lead to decreased levels of PA, 
decreased functional independence and poor quality of life.  However, in my 
study, the median time the patients were taking ARV medication was seven 
months, by which time most of the short term side effects associated with NRTI 
and NNRTI use had been resolved.  No difference in aerobic capacity, muscle 
strength and physical activity counts were seen between the HIV positive patients 
and HIV negative controls who participated in the physiological evaluation.  
These results suggest that the use of ARV medication is beneficial in improving 
and maintaining the functional capacity of HIV positive patients, despite the short 
term side effects. 
 
The long term side effects associated with ARV medication use include unwanted 
changes in body composition (lipodystrophy), impaired glucose metabolism 
(glucose intolerance and insulin resistance which can lead to the development of 
diabetes mellitus) and impaired lipid metabolism (dyslipidemia), including 
elevated tryglycerides and cholesterol (Department of Health, 2004; Cade et al., 
2003; Stringer et al., 2001; Grunfeld et al., 1992).  These symptoms are mainly 
associated with the use of protease inhibitors (PIs) but have also been associated 
with NRTIs and NNRTIs (Department of Health, 2004; Grimwood, 2004).  
Lipodystrophy manifests after approximately two years, diabetes mellitus after 
four years and dyslipidemia after five years (Chow et al., 2006).   
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No evidence of body wasting or lipodystrophy was observed in the HIV positive 
patients who were taking ARV medication.  This result is reflected in the BMI 
and WHR values obtained for these patients.  Although the BMI could be 
considered high by normal standards, these values are not uncommon in black 
females.  However, more accurate anthropometric protocols should be employed 
over a period of time to assess body composition changes.  Glycated hemoglobin 
(HbA1c) is used as an indicator of the average plasma glucose concentration over 
a period of approximately three months and is used as a clinical tool in the 
diagnosis of diabetes mellitus (Marshall et al., 2000; McCane et al., 1994).  In the 
physiological evaluation, the HIV positive patients had a significantly lower 
HbA1c level than the HIV negative controls, even though both results were within 
the normal range of 4.3% to 6.3% (Peters et al., 1996).  An HbA1c level of over 
7% is recommended as the cut off for diagnosing diabetes.  However, the HIV 
positive patients who participated in this research had only been taking ARV 
medication for a median time of seven months where it is unlikely that the long 
term side effects of ARV medication use would have manifested in that time 
period.  Also, fasting cholesterol levels were not measured which would provide 
some indication of the lipid metabolism of the HIV positive patients taking ARV 
medication.  It is difficult to determine if these long term side effects associated 
with ARV medication use will impact negatively on the habitual physical activity 
levels and functional status of these patients.  Therefore a longitudinal study 
monitoring the effects of long term adverse drug reactions on habitual physical 
activity levels and functional capacity should be conducted. 
 
5.2 Conclusion 
HIV is a rapidly growing epidemic despite high profile prevention campaigns and 
treatment advances.  People living with HIV are said to experience high levels of 
body impairments, activity limitations and participation restrictions.  With the 
introduction of antiretroviral (ARV) therapy, people infected with HIV have an 
improved immune function as well as a better quality of life.  However, little is 
known about the effect of HIV disease on a person’s habitual physical activity 
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levels as well as the effect of ARV use on exercise capacity and functional 
independence.  The results of my study have shown that the use of ARV 
medication improves the immune status of HIV infected individuals (reflected by 
a higher CD4 cell count), which translates into higher habitual physical activity 
levels and a greater sense of functional independence.  In addition, I have also 
shown that the use of ARV medication results in no physiological difference with 
regard to exercise capacity, muscle strength and measured physical activity counts 
between HIV positive patients and their HIV negative counterparts.  This result 
suggests that patients infected with HIV who are taking ARV medication are not 
at a disadvantage when performing tasks of daily living requiring some degree of 
endurance and are able to maintain their functional independence. 
 
5.3 Recommendations for future work 
This study provides a valuable foundation for future studies investigating the 
relationships between HIV infection and the physical well being of patients 
infected with HIV.  It is recommended that future studies focus on the effects of 
long term ARV use (greater than three years) on the habitual physical activity 
levels and functional well being of patients infected with HIV.  Therefore, a 
longitudinal study which follows patients over a long period of time starting from 
diagnosis and commencement of ARV treatment, should be conducted in order to 
effectively assess the impact of long term ARV medication side effects on the 
functional status of patients infected with HIV. 
 
When assessing the relationship between HIV infection and physical activity 
levels, it is recommended that potential confounders, such as age, gender, 
socioeconomic status, stage of disease, prevalence of opportunistic infections, etc. 
be taken into account.  This would enable a more accurate assessment of the 
factors that contribute to physical activity in this population.  Also, assessing the 
socioeconomic status of HIV positive individuals (and the South African 
population as a whole) is a complex issue with regard to income vs. area of 
residence etc. it is recommended that more detailed questions with regard to 
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socioeconomic data be asked to provide a more representative picture.  
Investigation of the mechanisms of how HIV infection affects a patient’s ability to 
remain functionally independent is also suggested for future work. 
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Appendix B 
 
LIFESTYLE AND PHYSICAL ACTIVITY QUESTIONNAIRE 
 
Please answer the following questions by crossing (X) the right block or writing down 
your answer in the space provided. 
 
Example of how to complete this questionnaire 
Gender 
If you are female 
Male 1 
Female X 
 
SECTION A – BACKGROUND INFORMATION 
This section of the questionnaire refers to background information. All results will be 
treated with absolute confidentiality.  Thank you for taking the time to fill in this 
questionnaire. 
 
1. Gender 
Male 1 
Female 2 
 
2. Age (in complete years) 
   
 
3. Race 
Black  1 
White 2 
Coloured 3 
Indian/Asian 4 
 
4. Home language 
English 1 
Afrikaans 2 
Zulu 3 
Sotho 4 
Xhosa 5 
Tswana 6 
Swazi 7 
Ndebele 8 
Venda 9 
Tsonga 10 
Other (please specify) 
______________________________ 
11 
 
5. Are you employed? 
Yes 1 
No 2 
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6. If yes, what is your occupation? 
  
__________________________________________________ 
 
7. How much do you earn per month? 
More than R20 000  1 
R10 000 – R20 000  2 
R5000 – R10 000 3 
R1000 – R5000 4 
Less than R1000 5 
I do not earn a salary 6 
 
8. What is your highest educational qualification? 
Post-graduate degree(s)  1 
Bachelor degree(s) 2 
Post Matric certificate/diploma  3 
Grade 12 (Matric, Std 10) 4 
Grade 8 (Std 6) – Grade 11 (Std 9) 5 
Grade 1 – Grade 7 (Std 5) 6 
I did not go to school 7 
 
9. How would you describe the area in which you permanently live? 
Upper class suburb 1 
Middle class suburb 2 
Low income housing project 3 
Township (formal settlement) 4 
Township (informal settlement) 5 
Traditional village 6 
I am homeless 7 
 
10. Which of the following amenities do have in your permanent home? 
Running water  1 
Electricity  2 
Flushing toilet inside your house 3 
Flushing toilet outside your house 4 
Working oven 5 
Working microwave  6 
Working television  7 
Working radio  8 
Working car  9 
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______________________________________________________________________________________ 
SECTION B – HIV INFORMATION 
 
THIS INFORMATION IS TO BE OBTAINED FROM PATIENT RECORDS 
 
11. When where you first diagnosed with HIV? 
0 – 6 months  1 
6 months – 1 year  2 
1 – 2 years 3 
2 – 3 years 4 
3 – 4 years 5 
4 – 5 years 6 
More than 5 years  7 
Unknown  8 
 
12. When was your last blood test to determine your CD4+ count? 
In the last 3 months 1 
3 months – 6 months ago 2 
6 months - 1 year ago 3 
1 – 2 years ago 4 
2 – 3 years ago 5 
3 – 4 years ago 6 
More than 4 years ago 7 
Unknown  8 
 
13. What is the patient’s current CD4+ count (in cells/mm3) 
 
 __________________________________________________ 
 
 
14. Are you currently on any of the following anti-retroviral medication? 
I am not on any medication 1 
3TC (Lamivudine)  2 
Combiver (Lamivudine + Zidovudine) 3 
Crixivan (Indinavir)  4 
Forte-Vase (Saquinavir) 5 
Invi-Rase (Saquinavir mesylate) 6 
Kaletra (Lopinavir + Ritonavir) 7 
Norvir (Ritonavir) 8 
Ritrovir (Zidovudine)  9 
Stavir (Stavudine) 10 
Stocrin (Efavirenz) 11 
Videx (Didanosine ddI) 12 
Viramune (Nevirapine) 13 
Zerit (Stavudine) 14 
Ziagen (Abacavir) 15 
Other (please specify) 
___________________________________ 
16 
 
15. If you are on antiretroviral treatment, for how long have you been taking the medication (in 
months)? 
 
 _________________________________________________ 
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16. Have you suffered from any of the following side effects since using anti-retroviral medication? 
I have not had any side effects from the medication 1 
Dizziness  2 
Nausea and/or vomiting 3 
Abdominal discomfort/pain 4 
Diarrhea  5 
Constipation  6 
Heart burn 7 
General fatigue 8 
Body mass loss 9 
Any kind of body pain (please specify) 
__________________________________________ 
10 
Other (please specify) 
__________________________________________ 
11 
  
17. Do you think that the antiretroviral treatment has increased or decreased your physical activity 
levels? 
Increased activity levels 1 
No change in activity levels 2 
Decreased activity levels 3 
 
18. Have you suffered from any of the following conditions in the past year? 
I have not been sick in the past year  
Pneumonia  1 
Tuberculosis  2 
Herpes  3 
Hepatitis  4 
Bacterial respiratory infections 5 
Kaposi’s sarcoma 6 
Other (please specify) 
___________________________________ 
7 
 
19. Have you suffered from any of the following symptoms as the result of being sick in the past year? 
Fatigue  1 
Sleepiness  2 
Depression 3 
Decreased appetite 4 
Lack of interest in appearance/grooming 5 
Decreased social behaviour 6 
 
20. Do you think that your physical activity levels have increased or decreased as a result of being 
sick in the past year? 
Decreased activity levels  1 
No change in activity levels 2 
Increased activity levels 3 
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______________________________________________________________________________________ 
SECTION C – INACTIVITY 
This section deals specifically with any condition or situation which results in inactivity. 
 
21. Have any of the conditions listed in questions 16 and 18 caused you to spend more than one week 
in a bed or chair? 
No 1 
Yes 2 
 
21.1 If yes, for how many weeks were you in a bed or chair? 
1 week 1 
2 – 4 weeks 2 
4 – 6 weeks 3 
6 – 8 weeks 4 
More than 8 weeks 5 
 
22. Do you have difficulty doing any of the following activities as a result of being HIV positive? 
Getting in or out of bed or a chair 1 
Walking across a small room without resting 2 
Walking for 10 minutes without resting 3 
Dressing yourself 4 
Washing/bathing yourself 5 
Getting in or out of a car/bus/taxi 6 
Working in your occupation 7 
Participating in recreational activity 8 
 
23. Approximately how many hours do you sleep at night? 
I do not sleep at night  
1 – 2 hours 1 
2 – 4 hours 2 
4 – 6 hours 3 
6 -8 hours 4 
8 – 10 hours 5 
10 -12 hours 6 
More than 12 hours 7 
 
24. Approximately how many hours do you sleep during the day? 
I do not sleep during the day 1 
1 – 2 hours 2 
2 – 4 hours 3 
4 – 6 hours 4 
6 -8 hours 5 
8 – 10 hours 6 
10 -12 hours 7 
More than 12 hours 8 
 
25. Do you think that your sleep is affected in any way by your HIV status? 
Yes  1 
No  2 
No opinion 3 
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26. In general, how many hours per day, during the week (Monday to Friday) do you spend watching 
television, listening to the radio or reading? 
1 – 2 hours 1 
2 – 4 hours 2 
4 – 6 hours 3 
6 -8 hours 4 
8 – 10 hours 5 
10 -12 hours 6 
More than 12 hours 7 
 
27. In general, how many hours per day, during the weekend (Saturday and Sunday) do you spend 
watching television, listening to the radio or reading? 
1 – 2 hours 1 
2 – 4 hours 2 
4 – 6 hours 3 
6 -8 hours 4 
8 – 10 hours 5 
10 -12 hours 6 
More than 12 hours 7 
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______________________________________________________________________________________ 
SECTION D – OCCUPATIONAL ACTIVITY 
This section focuses on any activity performed as a result of your occupation.  Only 
answer this section if you are employed. 
 
28. How many days per week do you work? 
1 day per week 1 
2 days per week 2 
3 days per week 3 
4 days per week 4 
5 days per week 5 
6 days per week 6 
7 days per week 7 
 
29. How do you travel to work? 
Walk 1 
Bicycle 2 
Car/bus/taxi/train 3 
I stay at my employer’s residence 4 
Other (please specify) 
___________________________________ 
5 
 
29.1. If you walk or cycle to work, at what pace do you walk or cycle? 
Brisk/fast   1 
Moderate/medium 2 
Leisurely/slow 3 
 
29.2. If you walk or cycle to work, how long does it take you to get to work and back home again? 
Less than 1 hour 1 
1 – 2 hours 2 
2 -3 hours  3 
3 - 4 hours 4 
More than 4 hours 5 
 
30. Approximately how many hours do you spend traveling per day, by car, bus, taxi or train? 
Less than 1 hour 1 
1 – 2 hours 2 
2 – 4 hours 3 
4 – 6 hours 4 
6 -8 hours 5 
8 – 10 hours 6 
10 -12 hours 7 
More than 12 hours 8 
 
31. At work, for how many hours do you sit per day? 
Less than 1 hour 1 
1 – 2 hours 2 
2 – 4 hours 3 
4 – 6 hours 4 
6 -8 hours 5 
8 – 10 hours 6 
10 -12 hours 7 
More than 12 hours 8 
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32. At work, for how many hours do you stand per day? 
Less than 1 hour 1 
1 – 2 hours 2 
2 – 4 hours 3 
4 – 6 hours 4 
6 -8 hours 5 
8 – 10 hours 6 
10 -12 hours 7 
More than 12 hours 8 
 
33. At work, for how many hours do you walk? 
Less than 1 hour 1 
1 – 2 hours 2 
2 – 4 hours 3 
4 – 6 hours 4 
6 -8 hours 5 
8 – 10 hours 6 
10 -12 hours 7 
More than 12 hours 8 
 
34. At work, do you lift heavy loads? 
Never 1 
Seldom 2 
Sometimes 3 
Often 4 
Always  5 
 
35. After work, are you tired? 
Never 1 
Seldom 2 
Sometimes 3 
Often 4 
Always  5 
 
36. Do you think that you are more tired after work than you were when you were HIV negative? 
Yes  1 
No  2 
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_____________________________________________________________________________________ 
SECTION E – HOUSEHOLD  ACTIVITY 
This section focuses on any activity that you do in your house. 
 
37. Please mark any of the following household activities which you do regularly.  Please fill in the 
following information: 
• Minutes per day (1 – 180min)  
• Days per week (1 – 7 days) 
• Weeks per month (1 – 4 weeks) 
• Months per year (1 – 12 months) 
 
 
No  Activity  Min/day Days/wk Wks/mnth Mnths/yr 
Eg Cooking 20 7 4 12 
1 Sweeping floors     
2 Heavy cleaning eg windows     
3 Mopping      
4 Washing dishes – standing     
5 Vacuuming     
6 Cooking – standing      
7 Food shopping – walking     
8 Ironing      
9 Scrubbing floors     
10 Carrying water      
11 Carrying wood     
12 Hanging up washing      
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______________________________________________________________________________________ 
SECTION F – RECREATIONAL ACTIVITY 
This section refers to any recreational or leisure time activity in which you have 
participated in the last year. 
 
38. Please mark any of the following recreational activities in which you have regularly participated in 
the past year.  Please fill in the following information: 
• Minutes per day (1 – 180min)  
• Days per week (1 – 7 days) 
• Weeks per month (1 – 4 weeks) 
• Months per year (1 – 12 months) 
 
No  Activity  Min/day Days/wk Wks/mnth Mnths/yr 
eg Soccer 30 3 4 6 
1 Bicycling for pleasure     
2 Circuit training (gym)     
3 Body mass training (gym)     
4 General health club exercise     
5 Running (treadmill)     
6 Rowing (machine)     
7 Ballet/modern dancing     
8 Aerobics      
9 Fishing      
10 General gardening     
11 Carpentry      
12 Jogging      
13 Running      
14 Badminton      
15 Basketball      
16 Bowls     
17 Boxing      
18 Cricket      
19 Rugby      
20 Golf (walking, carrying clubs)     
21 Golf (using golf cart)     
22 Gymnastics      
23 Hockey      
24 Horseback riding      
25 Judo, karate etc      
26 Orienteering      
27 Soccer      
28 Squash      
29 Tennis      
30 Volleyball      
31 Hiking      
32 Rock climbing      
33 Walking for pleasure      
34 Canoeing/ rowing for pleasure     
35 Sailing      
36 Skipping       
37 Swimming slowly     
38 Swimming fast      
39 Water aerobics     
40 Playing with children     
 
 
39. Do you think your physical exercise habits have been negatively affected by your HIV status? 
No  1 
Yes  2 
 
 
40. Are you interested in participating in an exercise test at the Wits Exercise Lab? 
Yes 1 
No 2 
 
41. If you would like us to contact you if you require more information, please provide a telephone 
number or email address in the space provided below.  Your details will remain confidential. 
 
Telephone number __________________________________________ 
 
Email address  __________________________________________ 
 
 Postal Address  __________________________________________ 
 
    __________________________________________ 
 
 
Thank you for taking the time to fill in this questionnaire.   
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